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ABSTRACT

INTERACTION BETWEEN DIETARY COMPONENTS AND GUT
MICROBIOTA AND ITS IMPLICATION IN BIOACTIVITIES AND
METABOLISM IN COLON

SEPTEMBER 2018

MIN GU
B.S., NANJING UNIVERSITY OF TECHNOLOGY, CHINA
M.S., SOUTH CHINA UNIVERSITY OF TECHNOLOGY, CHINA
Ph.D., UNIVERSITY OF MASSACHUSETTS, AMHERST, MA

Directed by: Professor Hang Xiao

The microbial cells that colonize the human body, including mucosal and skin
environments, are at least as abundant as our somatic cells and certainly contain far more
genes than our human genome. Gut microbiota dysbiosis is associated with the onset and
progress of several diseases, like diabetes, obesity, inflammatory bowel disease. One of
the environmental factor-diet intervention can modulate the compositions of gut
microbiota, which in turn may contribute to altered health outcomes such as changes in
the risks of chronic diseases. Orange peel has been a traditional herb in China, and some
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of its compounds has shown health benefits. However, to our knowledge, limited
information is available about the interaction between bioactive dietary compounds in
orange peel and gut microbiota. Firstly, we aim to study the metabolic fate of limonin and
how it will modify the gut microbiota in mice.
Unchallenged mice were fed a diet containing limonin (0.05% w/w) for 9 weeks.
Limonin distribution analysis revealed that most limonin was unabsorbed and persisted to
colon. During the 9-week feeding time, mice gut microbiota profile was altered
continuously. After 9 weeks’ dietary intervention, diversity of the mouse gut microbiota
was significantly enhanced compared with control group. In the meantime, the gut
microbiota community structures were markedly distinct between the two groups.
Limonin treatment significantly unregulated the abundance of 27 genera and
downregulated the level of 5 genera. Based on the analysis of Kyoto Encyclopedia of
Genes and Genomes (KEGG) database, 11 functional pathways were predicted to be
upregulated while 9 functional pathways were downregulated dramatically. Specifically,
the functional pathways related to the production of bacterial toxin and the
Staphylococcus aureus infection were suppressed dramatically with limonin treatment.
Here we observed that gut microbiota was changed by limonin supplementation.
We hypothesized that nobiletin, another major compound from orange peel, could alter
mice gut microbiota, which might contribute to host health benefits of nobiletin. In this
study, we determined the effects of dietary nobiletin intervention dextran sodium sulfate
(DSS)-induced colitis as well as the composition of gut microbiota in mice. The results
revealed that nobiletin treatment significantly decreased the severity of colonic
inflammation in DSS-treated mice, evidenced by the reduced production of pro-
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inflammatory cytokines (i.e., GM-CSF, INF-!, IL-1", IL-2, IL-6, KC/GRO, and TNF-#)
in the colonic mucosa, increased colon length, and decreased disease activity index and
histologic score of inflammation (p<0.05) by nobiletin treatment. Results from next
generation sequencing of the fecal microbiota showed that DSS treatment significantly
altered the microbial structure of fecal microbiota in mice, and dietary nobiletin treatment
trended to reverse these alterations. It was also demonstrated that DSS treatment
decreased the relative abundance of Bifidobacterium and Lactobacillus compared with
control (unchallenged) group. nobiletin treatment partially reversed the DSS-induced
decrease in these two genera in DSS treated mice. DSS treatment significantly increased
the abundance of Sutterella and Bilophila, while nobiletin effectively reversed DSSinduced increases in these two genera. Overall, our results for the first time suggested that
modification of gut microbiota by dietary nobiletin might contribute to its inhibitory
effects against the development of colitis in mice.
Besides, we found that gut microbiota in the colon involved the metabolism of
nobiletin and contributed to the anti-inflammation effect of nobiletin. Therefore, we
isolated and identified the bacteria with nobiletin metabolizing capacity. Bacteria Isolate
G7 was the potential one belong to species Bifidobacterium pseudocatenulatum, which is
commonly regarded as probiotic. Except the metabolizing ability, its secretion has strong
anti-inflammation effect by blocking the NF-$B pathway in Raw 264.7 cells. Isolate G7
secretion performed strong anti-cancer effect on human colon cancer cell HCT116 by
promoting cell apoptosis, arrest cell cycle at G2/M phase and downregulate the gene
expression of wnt signaling pathway.
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The oral delivery of probiotics to the colon is often difficult because they lose
viability when exposed to the harsh conditions in the upper gastrointestinal tract, such as
the highly acidic gastric fluids. Properly designed encapsulation technologies can be used
to protect probiotics during their transit through the human gut. In this study, an
anaerobic probiotic (Bifidobacterium pseudocatenulatum G7 or BPG7) was encapsulated
within alginate microgels that also contained antacid agents to control their internal pH
within the stomach. Probiotic-loaded microgels were exposed to a simulated
gastrointestinal tract (GIT) model to establish the impact of gastric and small intestinal
conditions on their physicochemical properties and cell viability. In the absence of
antacid, no live probiotic cells were detected in the microgels after exposure to
gastrointestinal conditions. Conversely, in the presence of antacid, there was only a 1.5
log CFU decrease in cell viability after incubation in simulated gastric fluids for 2 h.
After the antacid microgels were then incubated in simulated intestinal fluids, viable
probiotic cells were still detected when CaCO3 was used as an antacid but not when
Mg(OH)2 was used. Overall, these results indicate that alginate microgels containing
CaCO3 as an antacid were the most efficient at protecting the probiotic during passage
through the upper GIT. This novel encapsulation technology may be useful for the oral
delivery of probiotics to the gut in the form of functional foods or supplements.
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CHAPTER 1
INTRODUCTION
!

Over millions of years, microbes that have colonized and coevolved with
humans have gradually come to help regulate nutrition and metabolism processes and
train both innate and adaptive immune responses. are at least as abundant as our somatic
cells [1] and certainly contain far more genes than our human genome. An estimated
500–1,000 species of bacteria exist in human body at any one time during the lifespan
[2]. Considering the huge number and cohabitation with human, microbe has been
recognized as a new organ [3]. Researches have indicated that gut microbiota dysbiosis
has been associated with chronic diseases, including obesity[4], diabetes[5, 6],
cardiovascular disease [7, 8], inflammatory bowel disease (IBD) [9, 10] and cancer [11].
It’s the lifestyle rather than genetic modulated the microbiota more significant [12].
Among the lifestyle related factors, diet intervention is an important and easy controlled
method to help people preserve health or inhibit the onset or attenuate the progress of
disease.
Citrus fruit is common on people’s table in North America, and orange skin has
been a traditional herb in China. Limonin and nobiletin are majr compounds belong to
classes furanolactones and flavonoids. Limonin exerted anti-cancer [13-15] and anti-HIV
effects [16]. Nobiletin was studied for its anti-cancer, anti-inflammation effects. While
limited microbiota study has been included in neither of the two compounds.
In this dissertation, we studied the metabolic fate of limoin to confirm whether it
!
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can reach colon in rodent animals, and studied the microbiota composition and function
to test our hypothesis that dietary limonin intervention could modify mice gut microbiota
and help to preserve host wellness. Nobiletin has been proved for the beneficial effects on
obesity associated with inflammation in mice [17], while anti-inflammation effect in
colitic mice model was rare. Therefore, we studied the anti-inflammatory effect of
nobiletin in DSS-induced colitis in mice model. Besides, microbiota was observed to
investigate its role in nobiletin’s anti-inflammation effect.
On one hand, dietary component could modify gut microbiota structure, and on
the other hand dietary component can be metabolized by gut microbiota residing in gut.
Xenobiotic metabolism by gut microbiota will activate, deactivate or toxify the
compound. Our lab has found that gut microbiota in the colon could deconjugate the
nobiletin metabolite conjugates formed by Phase II metabolism in liver. What’s more, the
free form metabolites have distinctively stronger anti-inflammation activity than their
parent compound [18], indicating that gut microbiota metabolism activate the activity of
nobiletin. For the metabolic ability of gut microbiota is largely unknown. We’re
interested in figuring out the bacteria with the deconjugation capacity. Besides, residing
bacteria can contribute to host health by its secretion, like anti-inflammation[19].
Our long-term goal is to develop diet-based strategies that are safe and costefficient alternative approaches to improve human gut health. To reach that goal, the
overall objective of this project is to study the interaction between gut microbiota and
dietary component. Our central hypothesis is dietary component could modify gut
microbiota composition and function, which might benefit host health. Moreover,
nobiletin will be metabolized by specific bacteria living in colon. Our hypothesis has
!
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been cultivated on our lab’s preliminary data regarding the anti-inflammatory efficacy of
nobiletin, and stronger anti-inflammation effect of metabolites on cell RAW 246.7.
We will test our central hypothesis and achieve our objective by utilizing the
following four specific aims:
1.! Determine the gastrointestinal fate of limonin and its effect on mice gut micorbiota.
Mice will be fed a diet containing limonin (0.05% w/w) for 9 weeks and then
sacrificed. Limonin distribution in digestive system is determined LC-MS. GCMS is used to study the SCFAs in mice cecum to investigate the activities of gut
microbiota. Microbiota structure in distal colon will be studied by T-RFLP and
16S rRNA gene sequencing. QIIME will be used to analysis the microbiota data
to observe the changes of microbiota diversity and compositions led by dietary
limonin treatment. LEfSE will be applied to build cladogram figure and figure out
the differentiate taxonomic changes of gut microbiota. PiCRUST will be used to
study the functional changes of gut microbiota.

2.! Determine the effect of nobiletin on inflammation and gut microbiota in DSSinduced colitic mice. Mice colon length will be measures and disease activity
index will be recorded to study the inflammation degree of mice with the presence
or absence of nobiletin treatment. Histological study will be utilized to study the
colon mucosa structure. ELISA will be performed to determine the inflammatory
cytokines in colon mucosa. Mice feces will be subject to 16S rRNA gene
sequencing analysis to study the effect of nobiletin on mice gut microbiota in
colitic mice model.
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3.!Identify the bacteria with deconjugation capacity and characterize the bioactivities of
bacteria secretion. Human fecal sample will be collected, diluted and spread on GAM
agar to form single colonies. The in vitro fermentation will be performed between single
colonies and small intestinal content from mice fed with nobiletin. The collect
fermentation supernatant will be subjected to HPLC analysis to investigate the
deconjugation capacity of the isolated single colonies. Active single colony will be
subject to Sanger sequencing to identify the bacteria. Bacteria secretion during the 48

h fermentation time will be collect every 12 h to study the anti-inflammation and
anti-cancer effect. LPS-stimulated RAW 264.7 cell inflammation will be used to
study the anti-inflammation effect. Nitric oxide will be tested and the expression
of key enzymes will be analyzed by western blot. Human colon cancer cell
HCT116 will be utilized for anti-cancer study. Cell viability will be assessed by
MTT, cell cycle and cell apoptosis will be measured by flow cytometry, and the
expression of key proteins associated with cell cycle and cell apoptosis will be
checked by western blot to study the anti-inflammation effect. Besides, qRT-PCR
will be used to measure the gene expression for the wnt signaling in HCT116 with
or without bacteria secretion treatment.
4.!Develop an effective oral delivery system for the probiotic isolated. Probiotic we isolated will
be encapsulated in alginate microgels loaded with gastroprotective agent CaCO3 or
Mg(OH)2. Cryo-SEM will be used to study the internal structure of different

encapsulation microgels. Sample before simulated digestion, after simulated
gastric digestion and after simulated gastrointestinal digestion will be collect for
analysis. Physical properties will be measure, including surface potential and
particle size. Live/dead cells will be visuliazed by Confocal scanning laser
!

4!

microscopy. Plate culture method will be applied to counting the bumber of live
cells at different stages.
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CHAPTER 2
LITERATURE REVIEW
!

2.1 Overview of Human Gut Microbiota
2.1.1 Introduction to Human Gut Microbiota
The human gastrointestinal (GI) tract represents one of the largest interfaces
(250–400 m2) between the host, environmental factors and antigens in the human body.
In an average life span, around 60 tons of food pass through the GI tract, along with an
abundance of microorganisms from the environment. The collection of bacteria, archaea
and eukaryote inhabiting the GI tract is termed the ‘gut microbiota’ and has co-evolved
with the host over millions of years to form an intricate and mutually beneficial
relationship [20, 21]. The number of microorganisms inhabiting the GI tract has is no less
than human somatic cells, about 1014 cells [1]. As a result of the vast number of
bacterial cells in the body, host and the microorganisms inhabiting it are often referred as
a ‘superorganism’ [22, 23].
2.1.2 Development of Human Gut Microbiota
It’s generally believed that microbiota colonization starts from birth, while it is
challenged by the detected microbes in womb tissue, such as placenta [24, 25]. After
birth, the GI tract is rapidly colonized by microorganism from environment, with life
events such as illness, antibiotic treatment and diet changes causing chaotic shifts in the
microbiota [25, 26]. The mode of delivery also appears to affect the microbiota
composition, with vaginally delivered infants’ microbiota containing a high abundance of
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Lactobacilli during the first few days, reflecting the high dominance of Lactobacilli in the
vaginal microbial community [24, 27]. Conversely, the gut microbiota of C-section
delivered infants is delayed in the colonization of genus Bacteroides, but colonized by
facultative anaerobes such as Clostridium species [28, 29]. The fecal microbiome of
vaginally delivered infants resembles that of their mothers with 72%, for C-section
delivered babies, the percentage is downregulated to 41%[30]. In early stages of
development, the number of microbiota species is relatively low and the species are
mainly belonging to phyla, Actinobacteria and Proteobacteria [25, 31]. During the first
year of life, the microbiota species increases and composition trends towards a distinct
adult-like microbial profile with unique temporal patterns to its host [32]. By around 2.5
years of age, the composition, diversity and functional capabilities of the infant
microbiota resemble those of adult microbiota [25, 26]. In adulthood, the composition of
the gut microbiota is relatively stable, but it is still subject to perturbation by life events
[33]. By the age of 65 and older, the microbial community shifts, with increased
abundance of Bacteroidetes and Clostridium cluster IV, comparing with younger subjects
where cluster XIV is more prevalent [34]. In contrast, a separate study suggested that the
microbiota of a young cohort and an elderly population (70 years) were relatively
comparable, whilst the diversity of the microbiota from a cohort of centenarians was
significantly reduced [35]. In the elderly population, a significant relationship has been
identified between diversity and living arrangements, such as community dwelling or
long-term residential care [36].
2.1.3 Composition and Structure of Gut Microbiota
Compiled data from different studies identified 2172 species isolated from human
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beings, indicating the large diversity of microorganisms. Among them, more than 500
species are identified in the colon [20]. O'Hara et al. reported that the density increase
4
following the GI track. It is estimated that less than 10 cells per gram lumen content in
the upper GI tract while about 10

12

cell in the lower GI tract [37, 38]. Cohabited bacteria

at different site of GI track differs at not only the number but also the species. A study
analyzed the composition of bacteria in small intestine and colon and concluded that the
majority bacteria phyla in small intestine are Firmicutes and Actinobacteria while the
Fimicutes were enriched at colon [39]. The situation is similar in mice. In mice, the
small-intestine microbial community is largely dominated by Lactobacillaceae [40]. In
contrast, Prevotellaceae, Lachnospiraceae and Rikenellaceae have been shown to
dominate in colon [40, 41].
The colon is constituted by three different parts, epithelial surface, mucosa and
feces/lumen, in which the types of flourishing bacteria are different. Swidsinski et al.
indicated that Bacteroides, Streptococcus, Bifidobacterium only present in the feces [38,
42]. the abundance of Bacteroidetes appears to be higher in faecal/luminal samples than
in the mucosa [20, 43]. In contrast, Firmicutes, specifically Clostridium cluster XIVa, is
enriched in the mucus layer compared with the lumen [43]. Even in the same colon
mucosa, the gut microbiome differs at both composition and diversity at difference
mucosa regions [20, 44]. Interestingly, recent experiments in mice colonized with a
diverse specific pathogen-free microbiota showed that the outer mucus of the large
intestine forms a unique microbial niche and that bacterial species present in the mucus
show differential proliferation and resource utilization properties compared with that in
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intestinal lumen [45].
2.1.4 Role of Gut microbiota in Health
Owing to its large genomic content and metabolic complement, the gut microbiota
provides a range of health beneficial properties to the host. Some of the most important
roles of these microbes are maintaining the integrity of intestinal barrier function,
providing nutrients such as vitamins or protecting against pathogens. In addition, the
interaction between commensal microbiota and the mucosal immune system is crucial for
host immune system.
Colonic bacteria release different types of carbohydrate-active enzymes, which
endow them with the capacity to ferment carbohydrates generating metabolites such as
SCFAs [46]. Three predominant SCFAs, propionate, butyrate and acetate, are typically
found in a proportion of 1:1:3 in the GI tract [11]. These SCFAs are rapidly absorbed by
epithelial cells in the GI tract where they are involved in the regulation of cellular
processes such as gene expression, chemotaxis, differentiation, proliferation and
apoptosis [47]. In human gut, acetate is produced by most gut anaerobes, propionate is
mainly produced by Bacteroidetes, whereas the production of butyrate is dominated by
Firmcutes [48, 49]. Propionate is primarily absorbed by the liver, whilst acetate is
released into peripheral tissues [50]. Propionate is known for its beneficial effects in
humans acting on β-cell function [51] and attenuating reward-based eating behavior via
striatal pathways [52]. Butyrate has strong anti-inflammatory and anticancer potential
[49, 51] and is an important energy source for colonocytes [47]. Butyrate can inhibit
bacterial translocation and improve gut barrier function by promoting tight-junction
assembly and mucin synthesis [49]. SCFAs also play a role in hepatic lipid and glucose
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homeostasis via complementary mechanisms. In the liver, propionate can activate
gluconeogenesis, whilst acetate and butyrate are lipogenic [49]. SCFAs also contribute to
immune system and inflammatory response regulation [49]. Except SCFAs, microbial
metabolites have an impact role on intestinal barrier functions, epithelium proliferation
and the immune system also [53].
The GI microbiota is also crucial to the de novo synthesis of essential vitamins
which the host is incapable of producing [54]. Lactic acid bacteria are key organisms in
the production of vitamin B12, which cannot be synthesized by either animals, plants or
fungi [54, 55]. Bifidobacteria are main producers of folate, a vital vitamin involved in
host DNA synthesizing and repairing [56]. In addition, gut microbiota in human have
also been shown to synthesize in humans, include vitamin K, riboflavin, biotin, nicotinic
acid, panthotenic acid, pyridoxine and thiamine [57]. Colonic microbiota can also
metabolize bile acids that are not reabsorbed for biotransformation to secondary bile
acids [58]. The alteration of the co-metabolism of bile acids, branched fatty acids,
choline, vitamins (i.e. niacin), purines and phenolic compounds has been associated with
the progress of metabolic diseases such as obesity and type 2 diabetes [59].
There are many lines of evidence in support of a role for the gut microbiota in
affecting epithelial homeostasis [60]. Germ-free mice exhibit impaired epithelial cell
turnover which is reversed upon colonization with microbiota [61]. It has been
demonstrated also that bacteria could help to promote cell renewal and wound healing,
such as Lactobacilli rhamnosus GG [62]. Furthermore, several species have been
reported in enhancing epithelial integrity, for example, in the case of Akkermansia
muciniphila [63] and Lactobacillus plantarum [64]. Except the effect in modulating
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epithelial properties, bacteria are implicated in modulating mucus properties and
turnover. Germ-free mice have an extremely thin adherent colonic mucus layer, but when
exposed to bacterial products (peptidoglycan or LPS), the thickness of the adherent
mucus layer can be restored to levels observed in conventionally reared mice [65]. B.
thetaiotaomicron and F. prausnitzii are associated with the co-ordination of mucus
production [66]. R. gnavus E1, Lactobacillus casei DN-114 001 and B. thetaiotaomicron
can remodel mucin glycosylation, for example, by regulating glycosyltransferase
expression [67-69]. It is proposed that these functions mediate the ability of other
commensals or pathogens to colonize, potentially providing some commensal species a
competitive advantage for some commensal species in the gut [67].
The GI microbiota is also important for the development of both the intestinal
mucosal and systemic immune system as demonstrated by the deficiency in several
immune cell types and lymphoid structures exhibited by germ-free animals. A major
immune deficiency exhibited by germ-free animals is the lack of expansion of CD4+ Tcell populations. This deficiency can be completely restored by treating Germ-free mice
with polysaccharide A from the capsule of species Bacteroides fragilis [70]. This process
is mainly mediated via the pattern recognition receptors (PRRs) of epithelial cells, such
as Toll-like or Nod-like receptors, which are able to recognize the molecular effectors
that are produced by intestinal microbes. These effectors mediate processes that can
ameliorate certain inflammatory gut disorders, discriminate between beneficial and
pathogenic bacteria or increase the number of immune cells or PRRs [71]. Segmented
filamentous bacteria (SFB) is a class of anaerobic and clostridia-related spore-forming
commensals present in the mammalian GI tract, and can actively interact with the
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immune system [72]. Specifically, SFB are closely associated with the epithelial lining of
the mammalian GI tract membrane, stimulating the secretion of serum amyloid A1 by
epithelial cells [53]. Colonized SFB may also direct postnatal maturation of the gut
mucosal lymphoid tissue, trigger a potent and broad IgA response, stimulate the T-cell
compartment and upregulate intestinal innate defense mediators, indicating the immunestimulation ability of SFB [73]. Akkermanisa muciniphila has been reported to be
associated with protection effect against several inflammatory diseases [5, 74-77],
suggesting that this species possesses anti-inflammatory capacity [78]. Individuals
suffering Crohn’s disease has unbalanced microbiota in mucosa characterized by reduced
diversity of core microbiota and lower abundance of F. prausnitzii [79]. Therefore, F.
prausnitzii may be monitored to serve as the biomarker to help gut disease diagnostics
[80]. Recently, an anti-inflammatory protein released by F. prausnitzii was shown to
inhibit the NF-κB pathway in intestinal epithelial cells and prevent colitis in an animal
model [81].
The physical presence of gut microbiota also influences pathogen colonization by
competing for attachment sites or nutrient sources, and by producing antimicrobial
substances [82]. Antibiotics have a profound impact on the microbiota that alter the
microbiota composition and reduce diversity in the gut and lead to the proliferation of
pathogenic populations [83]. Dietary fiber deficiency, together with a fiber-deprived
mucus-eroding bacteria, promotes greater epithelial access and lethal colitis by the
mucosal pathogen Citrobacter rodentium in mice [84]. The gut microbiota, via its
structural components and secretions, also stimulates the host to produce various
antimicrobial compounds. These include AMPs such as cathelicidins and C-type lectins
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by the host Paneth cells via a PRR-mediated mechanism [85]. The other mechanism by
which the gut microbiota can limit pathogen overgrowth is by inducing mucosal SIgA
[86]. SIgAs induction directed against gut commensal bacteria occurs via M-cellmediated sampling mechanism [87]. SIgAs are then anchored in the outer layer of colonic
mucus through combined interactions with mucins and gut bacteria, thus providing
immune protection against pathogens whilst maintaining a mutually beneficial
relationship with commensals [88].
2.1.5 Gur Microbiota and Inflammatory Bowel Disease (IBD)
In United States and Europe, there are total 3.6 million people suffering from IBD
and the number is keeping increasing. There’re two major clinical phenotypes of IBD:
ulcerative colitis disease (UC) and Crohn’s disease (CD), refereeing the aberrant
inflammation in small intestine and colon. The importance of microbiota with IBD was
evidenced by researches that colitis is significantly attenuated or absent in germ/free
animals and those treated with antibiotics [89-91]. Specifically, Bacteroides,
Enterobacteriaceae, Porphyromonas, Akkermansia muciniphila, and Clostridium
ramosum are enriched in several animal models of IBD and are associated with higher
levels of inflammation [91]. In humans, there is an overall trend toward decreased
microbiome richness, higher abundance of Bacteroides and Enterobacteriaceae, and
lower abundance of Firmicutes in people with IBD compared with healthy people [92,
93]. Studies note a reduction of certain commensal microbes in IBD, particularly SCFAs
producers. These include Faecalibacterium prausnitzii (F. prausnitzii),
Leuconostocaceae, Odoribacter splanchnius, Phascolarctobacterium, and Roseburia
[94]. F prausnitzii and Roseburia hominis both are butyrate producer and their abundance
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are inversely correlate with disease degree of UC [95]. Furthermore, reduction of F
prausnitzii has been linked with postoperative recurrence of Crohn’s disease, and its
administration ameliorates gut inflammation in mouse [96]. Phascolarctobacterium
produces propionate in the presence of Paraprevotella, which stimulate the production of
Tregs [97]. At the same time, several pathogens are enhanced in IBD, including
Escherichia coli, Shigella, Rhodococcus, Stenotrophomonas maltophilia, Prevotellaceae,
Clostridium difficile, Klebsiella pneumoniae, Proteus mirabilis, and Helicobacter
hepaticus[9]. This unbalanced shift in favor of pathogens colonization is thought to lead
to perturbations in the immune function of lamina propria cells, ultimately resulting in
inflammation and progression to disease [10].
2.1.6 Diet Shaping the gut microbiota
Disruption to the balance of cohabited gut microbiota has been associated with
host metabolic disorders, such as obesity, diabetes, coronary heart disease [6, 98], and
inflammatory bowel disease [99], and it is also associated with neurodevelopment and
cognitive processes as well [100, 101]. However, human microbiota is sensitive to both
multiple host intrinsic and extrinsic factors. A newly published research indicated that
human microbiome composition is dominated by environmental factors rather than by
host genetics [12]. Extrinsic factors, especially diet, may be crucial in shaping the gut
microbiota. Levels of Prevotella were enriched in children from a rural African village
who consume high-fiber diet [102], whilst in children and adults from Malawi and
Venezuela with plant-derived polysaccharide dominated foods. By contrast, the
microbiota of those in USA has greater Bacteroide [103]. Bacteroides is associated with a
long-term diet enrich in animal protein, several amino acids and saturated fats, and
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Prevotella is correlated with carbohydrates and simple sugars [104]. Besides, small
molecules can help to restore the microbiota. For example, the fecal microbiota is
significantly altered and the gut physiology is markedly improved of after 4 weeks’
treatment of non-digestible fructans in high-fat induced obsess mice [105]. The
administration of small molecular photochemical quercetin restored the mice gut
microbiota from dysbiosis induced by high-fat sucrose diet in mice [106]. Therefore,
dietary interventions can be a viable strategy to restore or enhance gut microbiota
function depending on the desired outcome.
2.2 Bioactive Components from Orange Peel
2.2.1 Limonin
Limonin is a bitter white crystalline substance, widely found in citrus fruits such
as orange and lemon seeds. It belongs to a group of bioactive triterpenoid aglycone
derivatives named limonoids [107]. Limonin has been reported to possess various
beneficial health effects including anti-carcinogenic, anti-inflammation, antibacterial,
antiviral [13-15, 108]. Accordingly, they have been recognized as one of the most
important components of medical foods [109]. Limonin has low bioavailability due to the
large molecular size and lipophilic property[110]. Thus, it is believed that limonin may
evade digestion and absorption by the host during transit through GI tract. The
unabsorbed limonin may reach the colon intact and interact with the gut microbial
community. !
2.2.2 Nobiletin
Dietary nobiletin (5,6,7,8,3′,4′-hexamethoxyflavone), the major PMFs mostly
found in citrus fruits, has been demonstrated to be a potential anticancer [18, 111-113],
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anti-inflammatory [114, 115], neuroprotective [116] and anti-obesity and insulin
tolerance agent [117]. Previously, we demonstrated that nobiletin inhibited colon cancer
in azoxymethane (AOM)-induced colon carcinogenesis in rats [113] and AOM/dextran
sulfate sodium (DSS)-induced colitis-associated colon carcinogenesis in mice[18]. Three
demethylated metabolites of nobiletin were reported, and the total amount of three
metabolites was 20-fold higher than its parent compound, and two out of the three
metabolites were more efficient in cancer inhibition than its parent compoundnobiletin[113]. Herein, the anti-cancer and anti-inflammatory effects of nobiletin were
induced by not only nobiletin itself but also its metabolites produced by the gut
microbiota [18, 114]. The biotransformation of nobiletin by gut microbiota improved its
bioactivities. However, the influence of nobiletin on gut microbiota has been poorly
understood, and insights into this could reveal details on the initiation and development
of several diseases [118-120].
2.3 The effect of gut micorbiota on xenobiotic metabolism
Dietary xenobiotics can modulate gut microbiota composition and functions[121124]. Conversely, the gut microbiota can metabolize numerous xenobiotic compounds
found in our diet, including macronutrients, micronutrients and phytochemicals[125,
126]. Xenobiotics can be metabolized into active, inactive, or toxic metabolites.
Before entering systemic circulation, gut microbiota is a significant component of
first-pass metabolism. The gut microbiota may metabolize compounds prior to
absorption, after efflux from the intestinal epithelium or following biliary excretion
from the liver.
It was identified that members of the Gordonibacter genus in the Actinobacteria
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phylum in colon can metabolize ellagitannins [127, 128]. Ellagic acid released by
ellagitannins hydrolysis can be metabolized into several structurally related urolithins can
at very high in colon and blood[129]. Plant-derived two phytoestrogen, isoflavones and
lignans, are metabolized by a diverse range of gut bacteria, such as members of the
Actinobacteria, Bacteroidetes and Firmicutes phyla[130-132]. For instance, daidzin, is a
glycosidic isoflavone in soy products, which can be metabolized to equol by several
species of bacteria residing in the gut (for example, Enterococcus faecium, Lactobacillus
mucosae, Bifidobacterium sp. and Eggerthella sp.) by glycosidic cleavage and reduction
of an α,β-unsaturated ketone[133]. Several gut bacteria involved in the metabolism of
ligans (such as pinoresinol and secoisolariciresinol) includes E. faecalis, E. lenta, Blautia
producta, Eubacterium limosum, Clostridium scindens and Lactonifactor longoviformis,
and produced bioactive metabolites enterodiol and enterolactone[134]. Conversely,
microbial biotransformation may exacerbate the effect of harmful compounds that are
derived from the diet. The glucuronidated compounds produced in liver by phase II
metabolism are excreted into the small intestinal lumen through bile and flow into the
colon, where microbial β-glucuronidases could theoretically release the conjugate group,
reactivating the toxic compound and thereby augmenting its genotoxicity[135]. For
example, the activity of microbial β-glucuronidases may contribute to associations
between the risk of CRC and the intake of heterocyclic amines, which are compounds
formed during the charring of meat[135]. On the other sides, bacteria β-glucuronidases
could activate the bioactivity of xenobiotic or its metabolites [18]. Though a lot attention
has turn to the metabolic property of gut microbiota, limited information is available so
far.

!

17!

2.4 Bioactivities of bacteria secretions
In rodents, probiotics can benefit host by secreting surface molecules or secret
bioactive factors, which might help to stimulate host immune system. SCFAs produced
by gut bacteria is most well-known bacteria secretion, whose host benefits has been well
studied[47, 49, 51]. While biofactors released by gut microbiota is not limited to SCFAs,
there’re researches indicates that gut bacteria can produce other bioactive components.
Helicobacter pylori infection can be inhibited by Bacillus subtitis 3 fermentation
supernatant, in which the effective components were identified as at least two antibiotics. One was amicoumacin A with anti-inflammation capacity, and the other was
MICs[136]. Bifidobacterium infantis secretion improved human epithelia cells (T84) barrier
function by increasing the expression of tight junction protein in vitro, and the oral treatment of
bacteria secretion ameliorate gut inflammation, increased colon barrier function in IL-10-/- mice
model [137]. Conditioned medium of Bifidobacterium longum sup infantis attenuated IL-6
production in response to IL-1" through TLR-4 in cell H4- a human fetal small intestine
epithelial cell [19]. Gastric cancer cell growth was suppressed by ferrichrome, derived from
Lactobacillus casei ATCC334[138]. Studies centered at bioactivities of the bacteria secretion can
contribute the mechanism study of probiotic beneficial effects.

2.5 Oral delivery system for probiotics
Encapsulation of probiotics in colloidal delivery systems can improve the shelf life
and viability of probiotics during storage and in the GIT [139-141]. Encapsulation of
Lactobacillus casei 01 in alginate-starch beads improved cell viability during freezedrying and storage [142]. Encapsulation of B. longum in alginate microgels coated with
chitosan improved their survival during passage through a simulated GIT [139].
However, there are few studies showing that colloidal delivery systems can successfully
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preserve the viability of probiotics after 2 hours’ exposure to gastric conditions [139,
143]. The main reason for the poor gastric stability of probiotics encapsulated in
microgels is that hydrogen ions (H+) can easily diffuse through the hydrogel network and
inactivate the encapsulated bacteria. Previously, we prepared alginate microgels loaded
with an antacid agent, Mg(OH)2, that could neutralize hydrogen ions when they entered
the microgels and thereby maintain a neutral internal pH even when they were dispersed
in acidic gastric fluids [144]. These antacid microgels may therefore be particularly
useful for increasing the cell viability of probiotics for oral delivery.
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CHAPTER 3
THE GASTROINTESTINAL FATE OF LIMONIN AND ITS EFFECT ON MICE
GUT MICORBIOTA

3.1 Introduction
Human’s GI tract is colonized by environmental microorganisms rapidly after
birth [145]. After several years, the GI track microbial community becomes stable, and
the bacteria number reaches 1013 to 1014, close to total human body cell count [146]. The
interaction between gut microbiota and host is associated with host metabolic disorders,
such as obesity, diabetes, coronary heart disease [6, 98], and inflammatory bowel disease
[99], and it is also implicated in neurodevelopment and cognitive processes as well [100,
101]. Emerging evidence has suggested that the composition of the gut microbiota is
associated with several external elements, including host genome, diet, lifestyle, and the
use of xenobiotics (prebiotics or antibiotics) [147-149]. Of these factors, dietary
interventions can be a viable strategy to restore or enhance gut microbiota function
depending on the desired outcome. In a particularly illustrative example, the fecal
microbiota of high-fat diet induced obese mice was markedly shifted and the gut
physiology was significantly improved after the mice were treated with the non-digestible
fructans for 4 weeks [105].The administration of small molecular photochemical
quercetin restored the mice gut microbiota from dysbiosis induced by high-fat sucrose
diet [106].
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Limonin is a bitter white crystalline substance, widely found in citrus fruits such
as orange and lemon seeds. It belongs to a group of bioactive triterpenoid aglycone
derivatives named limonoids [107]. Limonin has been reported to possess various
beneficial health effects including anti-carcinogenic, anti-inflammation, antibacterial,
antiviral [13-15, 108]. Accordingly, it has been recognized as one of the most important
components of medical foods [109]. Limonin has low bioavailability due to the large
molecular size and lipophilic property [110]. Thus, it is believed that limonin may evade
digestion and absorption by the host during transit through GI tract. The unabsorbed
limonin may reach the colon intact and interact with the gut microbial community.
However, research regarding the interaction between limonin and gut microbiota is
limited. In this study, we examined the effect of limonin on gut microbiota in
unchallenged CD-1 mice. We hypothesized that limonin would evade metabolism on the
upper GI tract and persist to the colon, altering the gut microbiota.
3.2 Materials and methods
3.2.1 Animal and diet
20 male wide-type CD-1 mice (6-8 week of age) from Charles River Laboratories
(Wilmington, MA, US) were transported to the specific pathogen free (SPF) facility.
Mice were housed in an air-conditioned room (temperature 23±2 oC, 50±10% humidity,
12-hour light-dark cycle) with free access to water and basal diet. After 1-week
acclimation, 20 male mice were randomly assigned to limonin treatment group (10
mice/group, 5 mice/cage) and control group. The control group was fed with AIN93G
diet, while the limonin treatment group was fed with the AIN-93G diet containing 0.05%
(w/w) limonin. Fecal pellets from metabolic cage were collected and stored at -80 oC.
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After 9 weeks, mice were sacrificed with CO2 asphyxiation after overnight fasting. Stool
from distal colon were collected for colonic fecal microbiome analysis. This animal study
was based on protocol approved by the University of Massachusetts, Amherst
Institutional Animal Care and Use Committee (#2014-0079).
3.2.2 Sample preparation and liquid chromatography-mass spectrometry (LC-MS)
conditions
Limonin in all mice organs and the whole GIT was extracted based on the
methods by Liang et al. [150]. The obtained samples were re-dissolved in 50%
acetonitrile for LC-MS analysis (Model 2020, Shimadzu, Kyoto, Japan) on a Zorbax SBAq C18 column (150 mm × 4.6 mm, 5 µm, Agilent Technologies, USA) at a flow rate of
0.8 mL/min. The linear gradient elution condition was: started with 80% mobile phase A
(5% ACN/water, v/v)/20% mobile phase B (100% ACN) (v/v) for 5 min, then processed
to 80% B/20% A over 30 min, and held at 80% B for 5 min. The elution was monitored
on the m/z- 469.
3.2.3 Cecal short chain fatty acids (SCFAs) analysis
Cecum contents were homogenized with 6-fold volume of pure water, and
supernatants were obtained by centrifugation (12,000 rpm, 10 min, 4 °C), and then
filtered through a 0.22 µm membrane. A chromatographic system composed of a 6890 N
GC (Agilent Technologies Inc., Palo Alto, CA, USA) connected with an ion flame
detector and a mass spectrometry 5973N detector (Agilent) was used for quantification
and identification of cecum content SCFAs as described previously [151].
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3.2.4 Microbial DNA extraction
Total fecal DNA was extracted using QIAamp DNA Stool Mini Kit (Qiagen,
Valencia, CA, USA) following the manufacturer’s instruction with the addition of the
bead-beating step to increase yield. Extracted DNA quantity was measured with a
NanoDrop Spectrophotometer (Thermo Scientific, Waltham, MA, US) and quality was
verified with the gel electrophoresis.
3.2.5 Terminal restriction fragment length polymorphism (T-RFLP) analysis
The T-RFLP analysis was conducted as described previously [152]. Briefly, the
universal primers designed to anneal at specific sequence in bacteria 16S rRNA genes,
FAM 8F (5’-AGAGTTTGATCCTGGCTCAG-3’) and HEX 1492R (5’GGTTACCTTGTTACGACTT-3’) were labeled at the 5’ end with phosphoramidite dye
(Life Technology, MA, USA). PCR products were amplified with 2.0 U KAPA HiFi
PCR master mix (KAPA Biosystem, Wilmington, MA, US). Each PCR product (4 µL)
was visualized after electrophoresis on 1.0% agarose TAE gel after ethidium bromide
staining. The remaining PCR products were subjected to a PCR purification column.
The purified PCR products were aliquoted and digested separately with 15 U of
MspI, HaeI and HaeIII (Roche Diagnostics) in a total volume of 12 µL as recommended
by the manufacturer for 5 h at 37 ºC. The resulting fragments of different sizes were
electrophoresed in 4% (wt./ vol.) of polyacrylamide gel (Acrylamide/Bis, 19:1; Bio-Rad)
with 1.25 µM Buffer (Bio-Rad) at a constant voltage of 120 V for 4 h. In general, T-RF
size corresponds to specific bacteria groups.
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3.2.6 Microbial phylogenetic profiling by sequencing of the 16S rRNA gene
amplicon
PCR was performed to amplify the V3-4 regions of the16S rRNA gene, which
incorporates targeted primers and the Illumina overhang adaptor. The primer set was
developed by Illumina (16S Amplicon PCR Forward Primer =
5'TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGCCTACGGGNGGCWGCAG) and (16S Amplicon PCR Reverse Primer =
5’GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTA
ATCC)(Yasir et al., 2015). PCRs were performed in a 96 well format on a Veriti thermal
cycler (Life technology, Carlsbad, CA, US) with 2x KAPA HiFi Hotstart ReadyMix
(KAPA Biosystem, Wilmington, MA, US). After purification on AMPure XP beads
(Beckman Coulter, Danvers MA, US), a limited cycle PCR was performed using the
Nextera XT Index Kit (Illumina, San Diego, CA, US) to attach dual indices and Illumina
sequencing adapters, followed by an additional purification on AMPure XP bead. The
quantity of the purified PCR products was measured by Qubit dsDNA BR Assay kit (Life
technology, Carlsbad, CA, US) and the amplicon quality was estimated by ScreenTape
Assay on Tape Station 2200 (Agilent Technologies, Santa Clara, CA, US). After
quantification and qualification, samples were pooled in equimolar amount and pair-end
2×300 bp sequencing was performed on Illumina MiSeq platform (Illumina, San Diego,
CA, US).
3.2.7 Microplate growth assay
Lactobacillus plantarum ATCC BAA-793 (L. plantarum 793) and
Bifidobacterium longum subsp. longum ATCC 15707 (B. longum 15707) were got from
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the American Type Culture Collection (ATCC). The two strains were verified by Dr.
Sela’s lab [153]. In brief, two trains confirmed by Bifidobacterium-specific
phosphoketolase assay [154] and through microscope, and B. longum subspecies was
differentiated with PCR-based B.longum/B. infantis ratio analysis [155]. The two strains
were propagated in de Man-Rogosa-Sharpe (MRS; Oxoid, Hampshire, England) medium
supplemented with 0.05% (wt/vol) L-cysteine (Sigma-Aldrich, St. Louis, MO) [156] at
37 °C under anaerobic conditions (Coy Laboratory Products, Grass Lake, MI).
Growth phenotypes were monitored in a 96-well microplate. For each studied
strain, 2 'L of overnight culture was inoculated to 200 'L MR S medium with or without
different concentration of limonin (10 'M or 100 'M). The growth assay was conducted
anaerobically at 37 °C for 48 h by assessing optical density at 600 nm (OD600) using an
automated PowerWave HT microplate spectrophotometer (BioTek Instruments, Inc.,
Winooski, VT). Each strain was evaluated in biological triplicate with three technical
replicates. Bacterial growth kinetics were calculated with Wolfram Mathematica 10.3
Student Edition with the equation ΔOD(t) = ΔODasym{1/[1+exp(ktc-t)] - 1/[1+exp(ktc)],
where growth parameter ΔODasym is the growth level at stationary phase, k represents
the maximum growth rate, and tc is the inflection point’s location indicating the time
needed to reach the highest growth rate [157]. !
3.2.8 Statistical analysis
The sequencing data was processed by QIIME software pipeline v1.9.1[158]. In
general, the high quality (quality value>25) sequence data was demultiplexed. Sequences
were then clustered into operational taxonomic unites (OTUs) using open reference OTU
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picking was performed against Greengenes bacterial 16S rRNA database (13_8 release)
[159] with 97% similarity threshold.
α -diversity (diversity within sample community species richness) was determined
with ten iterations at a maximal sequence depth where all samples could be included. βdiversity (between sample communities dissimilarity) was calculated using weighted and
unweighted UniFrac distances [160]. To investigate the effect of limonin treatment on
relative abundance of taxa, Student’s t-test and linear discriminant analysis effective size
(LEfSe) analysis were performed.
Galaxy Phylogenetic Investigation of Communities by Reconstruction of
Unobserved States (PICRUSt) was used to explore the predicted functional metagenome
shifts between communities. According to the requirement form PICRUSt algorithm,
operational taxonomic unites (OTUs) were aligned to the Greengenes 16S rRNA
database using a closed reference picking protocol [161]. Statistical analysis was used to
compare functional shifts between groups in the STAMP software [162]. For all analyses,
statistical significance was declared if p < 0.05.
3.3 Results
3.3.1 Limonin has no effect on mice general properties
There was no difference in mouse initial body weights (results not shown), and
after an 8-week intervention period, there was no observed difference in mouse final
body weights (Control=39.08±1.83 g, Limonin=40.32±3.89 g, p=0.62) (Table 3.1).
Additionally, no differences were found for the liver or spleen weight (p=0.61 and
p=0.74), indicating that 500 ppm limonin diet has no toxicity to mice.
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Table 3.1 General property of mice fed with limonin
Group

Weight/g

Liver/mg

Spleen/mg

Control

39.08±1.83

1922.58±162.20

138.52±17.77

Limonin

40.32±3.89

2032.70±92.36

89.70±7.01

p value

0.62

0.61

0.74

3.3.2 Determination of limonin distribution in mice
To explore the effect of limonin on gut microbiota, it was critical to ensure
whether limonin could evade GIT metabolism and reach the colon to interact with gut
microorganisms. Herein, GIT tissues were subjected to limonin extraction and the
extracts were detected using LC-MS. As shown in Figure 3.1A, the concentration of
limonin increased following transit through the small intestine (SI) in the digesta, and the
concentration of stomach digesta was close to the SI-4. Mice cecum and colon were the
organs to further concentrate the limonin, and the limonin in colon digesta was as high as
523.14±95.67 nmoL/g tissue. However, limonin distribution in mucosa along the GIT
was different from the digesta (Figure 3.1B). Cecum mucosa had the highest limonin
concentration (15.02±3.80 nmoL/g tissue), which may be due to the long villi and
transition time. When compared to the high concentration of limonin in colon digesta,
limonin amount in the colon mucosa was low (3.82±1.17 nmoL/g tissue), which was only
0.7% of the amount in colon digesta. However, the highest concentration of limonin in
organs was 2.76±0.85 nmoL/g in spleen, which was near 50% of the average
concentration (5.43 nmoL/g) in GIT mucosa and 1.4% of the average concentration
(191.57 nmoL/g) in GIT digesta (Figure 3.1C). Limonin concentration in the liver and
plasma was all below 0.5 nmoL/g tissue. Taken the tissue weight into account, the
absorbed limonin was no more than 1% of the total administrated limonin (data not
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show). Therefore, we concluded that most of the limonin was unabsorbed, evaded the
GIT metabolism and accumulates in the distal colon digesta, in which lives the highest
density of bacteria (1011/mL digesta) [146].
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Figure 3.1!Limonin distribution in mice. (A) Limonin distribution in the digesta along the
gastrointestinal track (GIT) (nmoL/g digesta); (B) Limonin distribution in the mucosa
along the GIT (nmoL/g mucosa); (C) Limonin distribution in mice organs (nmoL/g).
3.3.3 SCFAs production in cecum
SCFAs are the end products of bacteria fermentation in cecum and colon. As a
measure of colonic microbial activity, fecal SCFAs concentrations were analyzed.
Limonin supplementation increased the production of 6 SCFAs (acetate, propionate,
isobutryric, butryric, isovaleric, and valeric). However, no significant differences were
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observed. (Figure 3.2). Since limonin itself couldn’t be the substrate of SCFAs
production, the insignificant changes may be due to the change of gut microbiota
composition. In consistent with most researches, acetate was the predominant SCFA in
the cecum [163, 164].
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Figure 3.2 Cecum short chain fatty acids (SCFAs). Data was shown as mean ±SD (n=5),
Student’s t-test was used to perform the statistical analysis, and no significant difference
was observed between control and limonin treatment groups.
3.3.4 Mice fecal microbial community structure changed with limonin treatment
At week 9, mice were sacrificed and distal colon feces were picked for T-RFLP
analysis to reduce the environmental contamination as much as possible. The microbial
community from the limonin group was significantly separated from the control group
(Figure 3.3), indicating that 9 weeks limonin treatment altered the fecal microbial
community profile.
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Control
Limonin
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Figure 3.3 T-RFLP analysis of gut microbiota structure change with limonin diet
intervention (at week 9).
3.3.5 Variation of fecal microbial community structure
To investigate the details about the microbial community shifts, colon fecal
samples were subjected to the microbial 16S rRNA gene sequencing on Illumina MiSeq
platform. A total of 953581 16S rRNA-based counts were obtained, with a mean of
95358.1 counts (range =56470-151193)/sample. The data set was rarified to 56470
sequences for analysis of diversity and species richness.
#-diversity including phylogenetic diversity whole tree matrix (PD_whole tree),
Observed OTUs richness, Chao1 and Shannon index were estimated using a linear mixed
model. Compared to the control, fecal microbiota species richness was increased by
limonin treatment significantly [observed species at the 97% level (OTUs):
3415.80±306.51 compared with 2305.60 ± 622.43, (p < 0.01); Chao 1 index: 7005.83 ±
578.54 compared with 5303.89 ±1375.58 (p < 0.03); and PD_whole tree (phylogenic
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branch distance): 101.06 ±8.76 compared with 81.31 ± 20.92 (P < 0.09)]. Even when
considering the evenness, the diversity of limonin treatment group was extremely
increased [Shannon index: 6.98 ± 0.26 comparing with 5.36 ± 0.39 (p<0.01)] (Table 3.2).
In addition, principal coordinates analysis (PCoA) of weighted and unweighted
UniFrac distances performed on the 97% OTU abundance matrix revealed a distinct
separation (p < 0.05) on the gut microbial community structures (β-diversity) between
limonin treatment and control groups (Figure 3.4A and 3.4B, respectively). ANOSIM
with 999 permutations was used to test the significant differences between the two groups
based on unweighted and weighted UniFrac [165]. As expected, limonin treatment
significantly shift the gut microbial community away from the control group (p=0.01 for
unweighted and p=0.003 for weighted), indicating that limonin
Table 3.2 Alpha-diversity of mice gut microbiota treated with limonin
PD_whole tree
Value
Control
Limonin

!

81.31±
20.92
101.06 ±
8.76

Observed OTUs

p value

Value

0.09

2305.60 ±
622.43
3415.80 ±
306.51

Chao1

p value

Value

0.01

5303.89 ±
1375.58
7005.83 ±
578.54

31!

Shannon index
p
value

Value

p
value

0.03

5.36 ±
0.39
6.98 ±
0.26

0.01

A

P=0.01

Control
Limonin

PC1 (29.59 %)
PC3 (11.57 %)

B

Control
Limonin

PC2 (11.54 %)

P=0.003

PC3 (4.16 %)

PC1 (79.67 %)
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Figure 3.4 Principal coordinate analysis (PCoA) of unweighted (A) and weighted (B)
UniFrac distance of fecal microbial communities performed on the 97% OTU abundance
matrix revealed a distinct separation (p<0.05) between limonin treatment group and
control group. Each dot represents a sample from each mouse (n=5) fed diets.

3.3.6 Taxomic shifts by limonin treatment
Greengenes classifier assigned usable raw reads to 9 phyla, 18 families, and 81
genera. The most abundant phyla included Firmicutes (49.10% of sequences),
Bacteroidetes (48.40% of sequences), Actinobacteria (1.24% of sequences),
Proteobacteria (0.354% of the sequences), TM7 (0.14% of sequences), Verrucomicrobia
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(0.02% of sequences), Deferribacteres (0.02% of sequences), and Tenericutes (0.01% of
sequences). Compared with the control group, phyla Proteobacteria and Bacteroidetes
were significantly enriched (from 0.04±0.01% to 0.354±0.14% p=0.0, and from
19.07±4.45% to 48.04±5.98%, p=0.03), while the phylum Actinobacteria was suppressed
significantly by limonin supplement (from 13.82±0.18% to 1.24±0.10%, p=0.03) and
Firmicutes decreased by 25% (from 65.39±2.90 to 49.10±6.09%, p=0.09).
To further explore the variation of microbial community composition between the
two groups, LEfSe test was performed to investigate the significant changes in relative
abundance (only average relative abundance >0. 01% included) of bacterial taxa at genus
level across samples. Our LEfSe analysis revealed that, 18 known genera (f_S24-7,
Bacteroides, Ruminococcus, Oscillospira, Dtreptococcus, Dorea, and so on) were
significantly enriched and five genera (Peptostreptococcaceae, Turicibacter,
Allobaculum, Bifidobacterium and Lactobacillus) were significantly decreased by
limonin treatment (LDA > 2.0, p < 0.05) (Figure 3.5). Our data demonstrate that limonin
treatment may dramatically impact microbial taxonomy when compared with the control.
Genus Oscillospira was increased from 0.33% to 2.95%, about 9-fold, which has been
associated with leanness in humans [166] and decreased incidence of inflammatory
bowel disease [167]. Unexpectedly, the genus Lactobacillus and Bifidobacterium were
both decreased significantly (43.99% to 13.17%, p=0.00, and 13.3% to 0.04%, p= 0.01).
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Figure 3.5 Gut microbiota genera represented between control and limonin treated groups
identified by linear discriminant analysis coupled with effect size (LEFSe) (LDA>2,
P<0.05). Red box: suppressed by limonin treatment, green box: enriched by limonin
treatment.
3.3.7 Variation of predicted functional metagenomes induced by limonin
supplement
Galax PICRUSt was used as a predictive exploratory tool. 18 level 2 KEGG
pathways were represented in the data set with significantly abundances shifts between
samples (Figure 3.6). Despite the accuracy of predictions being lower in other mammals
than for humans (mean NSTI = 0.03 ± 0.02), it can still provide useful information about
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functional predictions for mammalian microbiomes [161]. For level 2, we found that 9
KEGG pathways (Cell motility, Amino Acid Metabolism, Metabolism of Cofactors and
Vitamins, Signal Transduction, Lipid Metabolism, Biosynthesis of other Secondary
Metabolism, Transport and Catabolism, Immune System, and Neurodegenerative
Diseases) were significantly increased by limonin treatment, and 9 KEGG pathways
(Immune System Disease, Infection Disease, Signaling Molecules and Interaction,
Enzyme Families, Xenobiotic Biodegradation and Metabolism, Nucleotide Metabolism,
Translation, Cell Growth and Death, and Replication and Repair) were significantly
suppressed by limonin treatment (LDA > 2, p < 0.05) (Figure 3.6A). Particularly,
staphylococcus aureus infection belonging to infectious disease was markedly
downregulated by limonin treatment (LDA > 2, p < 0.05) (Figure 3.6B). In summary,
limonin treatment changed the profile of gut microbiota, which in turn could influence
gut microbiota functions and the health of the host.
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Figure 3.6 Microbial functional pathways significantly shifted with limonin treatment
using predictive metagenomics. (A) Functional pathway changes based on LEfSE
analysis. (B) The relative abundance of bacteria functional pathways associated with
Staphylococcus aureus infection. PICRUSt was used to predict the microbial
metagenomes from bacteria MiSeq data.
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3.4 Discussion
Limonin, a triterpene derivate from citrus fruits, has been recognized to have a
wide range of bioactive activities including a beneficial effect on colon health [13, 15,
108]. For example, it previously has been reported to inhibit the proliferation of human
colon adenocarcinoma (SW480) cells through mitochondria mediated intrinsic apoptosis
[108], and suppressed AOM-induced colon cancer in male rats [13]. In addition,
researchers found that limonin could be metabolized by some specific bacteria
(Acinetobacter sp.) from soil [168]. Thus, Limonin might interact with gut bacteria.
However, limited information has been reported about the effect of limonin on gut
microbiota. Therefore, we studied the effect of limonin on mice gut microbiota.
Oral ingested xenobiotics have diverse bioavailability, depending on each
compound’s properties. Oral bioavailability in human studies revealed that the
bioavailability of xenobiotic with molecular weight (MW) >400 was less than 20% [169],
while limonin has a MW of 470.52, indicating that limonin’s in situ bioavailability
should be below 20%. As expected, our results showed that a large fraction of the orally
administrated limonin was unabsorbed and persisted to the colon, interplaying between
diet and the gut microenvironment.
Our results indicated that the gut microbial community was shifted substantially
during the treatment time as the PCA figure showed distinct separation of fecal microbial
communities between control and limonin treatment groups (Figure 3.3A). It was
probably caused by the exposure to limonin that provided a selective advantage to certain
members of the community. At week 9, the distal colon fecal microbiota was subjected to
16S rRNA gene analysis, revealing that the gut microbial community (#-diversity and "!
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diversity) was strongly shifted by the limonin treatment. One important aspect of the
diversity is species richness (the number of species present in certain microbiota
ecosystem), which was significantly increased by limonin treatment. Communities has
higher species richness are more resistant to invasion as they are more efficient in
competing for limited resources [170]. Besides, higher species richness could improve
the stability of the host gut microbiota ecosystem [171]. On the opposite, obesity and diet
with high fat and sugar has been linked with decreased diversity comparing with low-fat
and plant based diet [172, 173].
Besides, the composition of the colon fecal microbiota was altered in response to
dietary treatment. At the phylum level, the relative abundance of Proteobacteria in
mice’s gut was significantly higher in limonin treatment group (p<0.05). The alteration in
relative abundance of Proerobacteria may results in a change in host energy
accumulation [174-176]. While, in our study, we didn’t see significant difference in
weight change during the experimental period. On the other hand, the phylum
Actinobacteria decreased dramatically (p=0.03) The relative abundance of Actinobacteria
would have different effects on host health depending on age and health status.
Previously , it shows that children suffering with autism had lower Actinobacteria in their
gut microbiota [177], while people with inflammatory bowel disease had higher level of
Actinobacteria [178]. The relative abundance of Bacteroidetes and Firmicutes are
typically reported to be associated with obesity where decreased F/B ratio is highly
related to the gut microbiota dysbiosis [4] and western high fat diet [179].The
inconsistent results may result from the sharing number of bacterial genera or species that
were altered, and their yet unknown health effects.
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The relative abundance of 23 genera were modified significantly by limonin.
Among them 18 genera were increased, while only 5 genera decreased in abundance.
Unexpectedly, the relative abundance of genus Bifidobacterium and Lacobacillus, which
are widely regarded as beneficial bacteria, are significantly decreased by limonin [180,
181]. To confirm the inhibition effect of limonin on the growth of Lactobacillus and
Bifidobacterium, the growth curve of two strain from the two genera was studied in vitro.
Interestingly, limonin significantly increased the maximum bacteria optical density,
reduced the time to reach the highest growth rate for both of two bacteria at the
concentration of 10 (M and 100 (M, much higher than the concentration in the mice
colon (Figure 3.7, Figure 3.8, and Table 3.3 and 3.4).
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Figure 3.7 The growth curve of B. longum subsp longum 15707 with limonin treatment at
different concentrations.
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Table 3.3 The growth parameters of B. Longum subsp Longum 15707 with limonin
treatment at different concentrations!

Control
Limonin 100 )M
Limonin 10)M

tc
13.93±0.39a
13.09±0.09b
12.66±0.26b

k
0.50±0.02
0.47±0.00
0.51±0.01

yasymp
1.32±0.01a
1.29±0.01b
1.34±0.00a

R^2
1.00
1.00
1.00
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Figure 3.8 The growth curve of Lactobacillus. plantarum 793 with limonin treatment at
different concentrations.
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Table 3. 4 The growth parameters of Lactobacillus plantarum 793 with limonin treatment
at different concentrations.!
tc
k
yasymp
R^2
Control
6.20±0.28
0.59±0.01
1.60±0.01
0.999
Limonin 100 (M
6.22±0.28
0.59±0.01
1.60±0.02
0.999
Limonin 10(M
6.22±0.28
0.58±0.02
1.61±0.01
0.999
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Herein, the significantly reduced abundance of Bifidobacterium and Lactobacillus
might due to the increased growth of the other bacteria, or reduced excretion of these
bacteria into the colon digesta. The increased diversity of gut microbiota community
should be associated with the increased growth of some non-dominant bacteria. In
addition, the reduced excretion of Lactobacillus and Bifidobacterium would be
potentially associated with the increased colonization in the mucosa, which could interact
with host immune response [182, 183]. Thus, the effect of limonin on Bifidobacterium
and Lactobacillus colonization on mucosa would be determined in future study.
Three out five genera in Phyla Bacteroidetes were significant increased, including
Bacteroides, f__Rikenellaceae; other and f_S24-7. Certain commensal Bacteroides
species could induce IBD in dnKO mice with or without antibiotic pretreatment, and
innate and adapted immune responses were activated in a host-genotype-specific fashion
[184]. The increased abundance of f_S24-7 could contribute to the plant carbohydrate
fermentation [185]. In phylum Firmicutes, 23 genera were increased more or less, and the
most significant ones were o__Clostridiales;f__;g__, f__Lachnospiraceae;Other,
[Ruminococcus], Oscillospira and Ruminococcus. The genus Oscillospira was negative
correlated with body mass index (BMI) and inflammatory disease [166, 186]. The genus
Ruminococcus was increased by 9-fold, which might enhance the gut microbiota ability
in degrading and utilizing fiber and carbohydrate in diet [187]. No significant changes
were observed for the genera in Phylum Proteobacteria, TM7, Tenericutes and
Verrucomicrobia.
Knowing the composition changes alone was not enough to know how the
limonin treatment could influence the host gut ecosystem, and we need to know its
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function shifts. Our PICRUSt analysis revealed that predicted genes from the
metagenome related to cellular processes and human disease were significantly increased
in limonin-treated samples. Xenobiotics Biodegradation and Metabolism were reduced,
whereas limonene and pinene degradation was increased, which was consistent with the
increased environmental adaption. Bacterial toxin behavior was reduced. Besides, the
immune system behavior was predicted to be enhanced, and the primary
immunodeficiency was reduced. Infectious disease signals were decreased, with the most
significant changes being associated with Staphylococcus aureus infection, which was
decreased to 22% (p=0.001) (Figure 3.6B). These results indicated that the changes
measured in the gut microbial community with limonin treatment may be beneficial for
our immune system and our human health.
3.5 Conclusion
In summary, this study investigated the influence of 9-week oral admission of
limonin on the mice gut microbiota. No significant changes in physical characteristics
(bodyweight, spleen, heart, liver and kidney) were observed in mice. Our study
confirmed that limonin could evade metabolism through GI track and persist to the colon.
The gut microbiota community was modified significantly, and the microbiota function
was also altered in response to dietary intervention.
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CHAPTER 4
ANTI-INFLAMMATORY EFFECT OF NOBILETIN WAS ASSOCIATED WITH
ALTERED GUT MICORBIOTA

4.1 Introduction
Inflammatory bowel diseases (IBD) is a kind of heterogeneous chronic and
relapsing inflammatory disorder, which will cause epithelial dysfunction or increasing
mucosal permeability of gastro-intestinal track. In the past decade, IBD has emerged as a
public health challenge worldwide [188]. Currently survey reported that the prevalence of
IBD in North America, and many countries in Europe exceeded 0.3% [189]. Multiple
research proved that the pathogenesis of IBD is correlated with dysregulated gut
microbiota [190-192]. The importance of microbiota with IBD was evidenced by
researches that that colitis is significantly attenuated or absent in germ/free animals and
those treated with antibiotics [89-91]. And comparing with healthy individuals, the gut
microbiota composition and structure in IBD patients is significantly disrupted, with an
increase in certain opportunistic pathogens and a decrease in beneficial bacteria [192].
This dysbiotic shift in favor of pathobionts is thought to contribute to perturbations in the
immune function of lamina propria cells, ultimately resulting in inflammation and
progression to disease [10].

!

43!

However, Human microbiota is sensitive to both multiple host intrinsic and
extrinsic factors. A newly published research indicated that human microbiome
composition is dominated by environmental factors rather than by host genetics [12].
Cultural factors, especially diet, may be crucial in shaping the gut microbiota. The ratio
of two of the main genera of gut bacteria, Prevotella and Bacteroides, correlates well
with the overall pattern of diversity across healthy adults (see discussion of entero-types
later) [104, 193]. Levels of Prevotella were enriched in children from a rural African
village who had a high-fiber diet [102], and in children and adults from Malawi and
Venezuela whose diet was dominated by plant-derived polysaccharide foods such as
maize and cassava. By contrast, the microbiota of those in the United States had more
Bacteroide [103]. For healthy adults in the United States, differences in long-term diet
between individuals also was correlated with these bacteria. Bacteroides was associated
with a long-term diet rich in animal protein, several amino acids and saturated fats, and
Prevotella was associated with carbohydrates and simple sugars [104]. The relative
importance of changes in the microbiota as a result of diet, compared with other factors
that affect health, remains a subject of active investigation. Besides, small molecules can
help to restore the microbiota also. In a particularly illustrative example, the fecal
microbiota of high-fat diet induced obese mice was markedly shifted and the gut
physiology was significantly improved after the mice were treated with the non-digestible
fructans for 4 weeks [105].The administration of small molecular photochemical
quercetin restored the mice gut microbiota from dysbiosis induced by high-fat sucrose
diet [106].Therefore, dietary interventions can be a feasible strategy to restore or enhance
gut microbiota function depending on the desired outcome.
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Dietary nobiletin (5,6,7,8,3′,4′-hexamethoxyflavone), the major PMFs mostly
found in citrus fruits, has been demonstrated to be a potential anticancer [18, 111-113],
anti-inflammatatory [114, 115], neuroprotective [116] and anti-obesity and insulin
tolerance agent [117]. Previously, we demonstrated that nobiletin inhibited colon cancer
in azoxymethane (AOM)-induced colon carcinogenesis in rats [113] and AOM/dextran
sulfate sodium (DSS)-induced colitis-associated colon carcinogenesis in mice[18]. Three
demethylated metabolites of nobiletin were reported, and the total amount of three
metabolites was 20-fold higher than its parent compound, and two out of the three
metabolites were more efficient in cancer inhibition than its parent compoundnobiletin[113]. Herein, the anti-cancer and anti-inflammatory effects of nobiletin were
induced by not only nobiletin itself but also its metabolites produced by the gut
microbiota [18, 114]. The biotransformation of nobiletin by gut microbiota improved its
bioactivities [18]. However, it’s still unclear, whether gut microbiota involved in the
bioactivities of nobiletin except biotransformation or not.
Herein, the aim of this study was to investigate the effect of nobiletin on mice gut
microbiota and the relationship between gut microbiota and inflammatory response in
mice to provide key information to lay fundamental information for health benefits of
dietary bioactive compounds.
4.2 Materials and methods
4.2.1 Animals, diets and experimental procedure
The protocol for the animal experiment was approved by Institutional Animal
Care and Use Committee of University of Massachusetts Amherst (#2014-0079). 30 male
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wild-type CD-1 mice (6-8 weeks old) were obtained from Charles River Laboratories
(Wilmington, MA, USA) and kept in a temperature-controlled animal room of 22 ± 2 °C
and 50 ± 10% humidity in a 12-h light-dark cycle with free access to water and a basal
diet. The mice were randomly divided into 3 groups (n=10/group) to receive either
standard chow (AIN-93G diet) or nobiletin diet. Nobiletin diet is made of AIN93G diet
mixed with 500 ppm nobiletin powder. After one-week acclimation with chow diet, the
three groups were distributed as follows: the control group, which was fed with standard
chow diet and regular water; the DSS group, which received chow diet and 1.5 % DSS
water (wt/v, dextran sulfate sodium salt, average molecular weight 36,000–50,000)
(International Lab, Chicago, IL, USA); the DSS+Nobiletin group, which received the
nobiletin diet and 1.5% DSS drinking water (wt/v). All experimental groups were
provided with respective drinking water ad libitum for 4 days followed by 1 week of
regular water for recovery, and this cycle was repeated for times. The weight of the mice
was recorded every other day during the whole experiment. At the end of the fourth
cycles of DSS water treatment, all mice were sacrificed by CO2 asphyxiation. The entire
colons were removed and rinsed with PBS, the weight and the length of the colon then
were measured and recorded. After measurement, the whole colon was opened
longitudinally and cut into two part longitudinally then kept separately for further
analysis. One part of the colon was stored at -80 °C for ELISA analysis while the other
part was first fixed in 4% buffered formalin (pH 7.4) for 24 h for further
histopathological and immunohistochemically analysis. The fecal pellets were collected
from the colon and stored at -80°C for further microbiota analysis. Both the liver and the
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spleen were dissected from the body and weighted for evaluation of disease progression
of ulcerative colitis.
4.2.2 Disease activity index (DAI) and histological evaluation of colon
Disease activity index were determined basing on the scoring for weight loss,
stool consistency and rectal bleeding, which were recorded every other day [194]. For
histological evaluation, the fixed colon segments were first dehydrated by using ethanol
and isopropanol, then were embedded in paraffin. The specimens were then sectioned
into slides, which get stained by hematoxylin and eosin (H&E). Histological grading was
evaluated based on the inflammatory criteria as described by Park et al. [195].
4.2.3 Enzyme-linked immunosorbent assay (ELISA)
Intestinal mucosa was collected and bead homogenized in lysis buffer (0.4 M
NaCl, 0.05% Tween-20, 0.5% BSA, 0.1mM benzethonium, 1% protease inhibitor
cocktail (Boston Bioproducts, Ashland, MA, USA)). Sample supernatants were collect
after centrifugation (10,000*×*g, 30 min, 4 °C), and protein concentration in the
supernatant was detected with BCA method [196]. The supernatant samples were loaded
in sandwich enzyme-linked immunosorbent assay (ELISA) kits (Meso Scale Diagnostics,
LLC, Rockville, Maryland, USA) to measure the concentrations of 10 inflammatory
cytokines.
4.2.4 16S rRNA gene sequencing
Total genomic DNA in mice feces was extracted with QIAamp DNA Stool Mini
Kit (Qiagen, Valencia, CA, USA), according to the manufacturer’s protocol with the
addition of mild bead-beating step to increase yield.
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Extracted DNA quantity was measured with a NanoDrop Spectrophotometer
(Thermo Scientific, Waltham, MA, US) and quality was verified with gel electrophoresis
and imaging. To characterize the microbial profile of each sample, the hypervariable
regions V3-4 of the genes encoding the 16S rRNA were sequenced from the extracted
DNA. PCR was performed to amplify the V3-4 region, which incorporates targeted
primers and the Illumina overhang adaptor. The PCRs were performed in a 96 well
format on a Veriti thermal cycler (Life technology, Carlsbad, CA, US) with 2x KAPA
HiFi Hotstart ReadyMix (KAPA Biosystem, Wilmington, MA, US). After purification
with AMPure XP beads (Beckman Coulter, Danvers MA, US), a limited cycle PCR was
performed with the Nextera XT Index Kit (Illumina, San Diego, CA, US) to attach dual
indices and Illumina sequencing adapters, followed by an additional purification with
AMPure XP bead. The quantity of the purified PCR products was measured by Qubit
dsDNA BR Assay kit (Life technology, Carlsbad, CA, US) and the amplicon quality was
estimated by ScreenTape Assay on Tape Station 2200 (Agilent Technologies, Santa
Clara, CA, US). After quantification and qualification, samples were pooled in equimolar
amount and pair-end 2×300 bp sequencing was performed on Illumina MiSeq platform
(Illumina, San Diego, CA, US).
4.2.5 Statistic analysis
The sequencing data was processed by QIIME software pipeline v1.9.1[158]. In
general, the high quality (quality value>25) sequence data was demultiplexed. Sequences
were then clustered into operational taxonomic unites (OTUs) using open reference OTU
picking against Greengenes bacterial 16S rRNA database (13_8 release) [159] with 97%
similarity threshold.
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α-diversity (diversity within sample community species richness) was determined
with ten iterations at a maximal sequence depth where all samples could be included. βdiversity (between sample communities dissimilarity) was calculated using weighted and
unweighted UniFrac distances [160].
Galaxy’s Phylogenetic Investigation of Communities by Reconstruction of
Unobserved States (PICRUSt) was used to explore the predicted functional metagenome
shifts between communities. According to the requirement form PICRUSt algorithm,
operational taxonomic unites (OTUs) were aligned to the Greengenes 16S rRNA
database using a closed reference picking protocol [161]. Functional profiling and
comparing was performed with STAMP software [162]. Unpaired Students’t-test was
used to calculate the statistical difference between the two groups. The results were
considered statistically significant at p < 0.05. Pearson correlation was examined in SPSS
Statistics, and cluster and heatmap was created in R.
4.3 Results
4.3.1 General observations
In this study, DSS was used to induce the colonic inflammation in mice and antiinflammatory effect by nobiletin was evaluated. At day 32, DSS induced severe illness in
mice which evidenced by a dramatically higher DAI scores (including weight loss,
diarrhea and evident rectal bleeding) (Table 4.1). Dietary nobiletin intervention
significantly decreased the DAI scores compared with DSS group. It is generally
accepted that colon length is negatively correlated with the severity of colitis in mice. As
shown in Table 4.1, a significant shortening of colon length was observed in mice treated
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with DSS compared with control mice (p<0.05), while nobiletin treatment had reversed
the change. The mean liver weight in DSS group was much lower than Control group,
while DSS+Nobiletin group has significantly greater liver weight than DSS group
(p<0.05) (Table 4.1). However, there were no pathological alterations suggesting toxicity
of test compounds in the liver, kidneys, lung, and heart of mice (data not shown).
Table 4. 1 Disease activity index (DAI), spleen weight colon length and histological
score of each group.
Group
Control
DSS
DSS+P1
c
a
DAI
0
2.26±0.20
1.56±0.17b
Colon
84.95±2.52a
69.57±2.98b
76.02±6.27ab
length/mm
Liver weight/g 2392.37±181.66a
1808.42±59.48c
2197.81±90.22b
Histological
0c
6.00±0.58a
2.67±0.88b
score

4.3.2 Effects of dietary nobiletin on the histological changes and expression of
inflammatory cytokines
The potential of dietary nobiletin on histological damages in the colons were
examined following the histological grading system as described [195]. Colonic
inflammation is characterized by severe lesions in the colon mucosa, alteration of
epithelial structure, increase in neutrophil population and lymphocyte infiltration into the
mucosal and submucosal layers, and loss of normal crypts. The colon specimens from the
negative control group showed normal features of typical glands, abundant goblet cells in
epithelium. In contrast, the colonic specimens obtained from the DSS group showed
serious erosive lesions with extensive loss of glands, cellular infiltration of immune cells
into the submucosa and lamina propria and crypt shortening, resulting in a high
histological score (Table 4.1). However, in the DSS+Nobiletin group, dietary nobiletin
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remarkably reduced the total histological score compared with the DSS group. The
colonic specimens had no erosion with just mild inflammatory cell infiltration. In both
control group and control-cranberry group, no aberrant tissue was observed (Figure 4.1A,
Table 5.1).
Figure 4.1B showed the concentration of three significantly changed
inflammatory cytokines (IFN-!, IL-10 and KC/GRO) in mice serum. Among the three
groups, DSS group has the highest concentration of anti-inflammatory cytokine IL-10,
while control group has the lowest level (p<0.05); nobiletin treatment increased the level
of inflammatory cytokines IFN-! and KC/GRO comparing with DSS group. As shown in
Figure 4.1 C and D, the expression of eight immune cytokines in colon mucosa were
different from that in serum. For all the eight cytokines (IFN-!, GM-CSF, IL-2, IL-10,
TNF-# KC/GRO, IL-1", and IL-6), DSS group had greater expression than both control
and DSS+Nobiletin group (p<0.05), indicating that nobiletin suppressed the
inflammatory response in colon mucosa.
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Figure 4. 1: Dietary nobiletin intervention reduced colon inflammation in mice. (A) HE
staining of mice colon mucosa. (B) The expression level of immune cytokines in mice
serum. (C and D) The expression level of inflammatory cytokines in mice colon mucosa.
4.3.3 Impact of nobiletin on mice gut microbiota
4.3.3.1 Microbiome diversity
An average of 173219.8 counts/sample was passed the filters applied through the
QIIME, and were clustered into 1406 identified OTUs (data not shown). All samples
were rarefied to 67143 sequences to run the α- and β-diversity analysis, the lowest
number of reads obtained from all sample datasets. Shannon index and Simpson value are
indicators for evenness of the bacteria community in each group. Nobiletin interruption
didn’t influence the evenness of microbiota community, and was much lower than the
control group (Figure 4.2), indicating that nobiletin treatment was too weak to increase
diversity of gut microbiota community.
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Figure 4. 2: Evenness of gut microbial community within the three mice groups
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The UniFrac Principal Component Analysis (PCoA) based on the relative
abundance of OTUs from each sample provided the information about the phylogenetic
relationship among the fecal bacterial microbiota in all study groups. The unweighted
PCoA figure we observed that DSS treatment separated the microbiota structural of the
microbial community from the Control group, while nobiletin intervention attenuated the
alteration as DSS+Nobiletin group was much closer to the Control group (Figure 4.3).
ANOSIM with 999 permutations was used to calculate the significant separation the three
groups with distance matrices of unweighted UniFrac. As expected, Bacteria community
of DSS group separated from both Control and DSS+Nobiletin groups extremely
(p<0.01). Moreover, microbiome community of DSS+Nobiletin group was significantly
different from the Control group (p< 0.05). These suggested that the nobiletin diet could
alleviate the gut microbiota disruption by DSS treatment.

!

53!

!

PC2 (9.43%)

Control
**
DSS
**
DSS+Nobiletin

*

PC1 (15%)
PC3 (7.7%)

!

Figure 4. 3: Principal coordinate analysis (PCoA) of unweighted UniFrac distance of
fecal microbial communities performed on the 97% OTU abundance matrix revealed a
distinct separation (p<0.05) among three groups (red dot indicated samples from Control
group, blue dot indicated samples from DSS group, and yellow dot meant the sample
from DSS+Nobiletin group). Each dot represents a sample from each mouse (n=5) fed
diets.
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In this study, significant variations of bacteria composition were observed among
the three groups. Firmicutes, Bacteroidetes, Proteobacteria, Verrucomicrobia and
Actinobacteria were five major phyla in mice colon fecal microbiota (Figure 4.4), which
was consistent with other mice gut microbiota research [197]. Linear discriminant
analysis (LDA) effect size (LEfSe) was applied to determine differentially relative
abundant bacterial phyla among the three groups (Figure 4.4). As observe din the figure,
DSS group has great higher abundance for phyla TM-7 and Proteobacteria, while
!
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nobiletin intervention promoted several genera in phyla Firmicutes and
Verrucomicrobiota. At the genus level, DSS+Nobiletin group has greater abundance of
Turicibacter, Dehalobacterium, Dorea, Lachnospiraceae, Akkermansia (p<0.05). DSS
group was much higher abundance for 6 genera (p<0.05), such as Parabacteroides,
Ruminococcus, rc4-4, F16, and Bilophia. For the commonly recognized probiotics,
Bifidobacterium and Lactobacillus, Control group has much higher abundance. These
results indicated that nobiletin diet could reverse the changes induced by DSS, while
there’re some differences between Control and DSS+Nobiletin groups.
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Figure 4. 4: LEfSe identified the most differentially abundant taxons among the three
groups. Taxonomic cladogram obtained from LEfSe analysis of 16S sequences

!

55!

(relative abundance ≥ 0.1%). (Red) Control-enriched taxa; (Green) taxa enriched in
DSS group; (Blue) taxa enriched in Nobiletin treated colitic mice. The size of each dot
is proportional to its effect size.
4.3.5 Predicted microbiome functions
Given the modification of microbiota profile following the exposure to dietary
nobiletin in colitic mice, Galaxy’s PICRUSt was used as to explore the gut microbiota
functions and the metagenomic functional pathways were predicted based on KEGG
database [161]. DSS and DSS+Nobiletin groups were far separated for the microbiome
community structure, while the functions were much closer as shown in the PCA figure,
and both were separated from the Control group (Figure 4.5 A). The expression of 12
functional pathways were significantly modified (Figure 4.5 B). It’s obvious that the
significance mainly caused by DSS, while the effect of nobiletin on the gene expression
was weak. Therefore, changes of gene expression and bacteria composition might not be
consistent.
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Figure 4.5: Predicted gut microbiome functions among the three groups based on KEGG
database. (A) PCA figure of gut microbiota functions among the three group. (B) The
gene copy numbers of samples within the same sample group were pooled. Ratio of each
functional gene to references was made and the significant enrichment and deplete was
shown in the heatmap at the second level of KEGG pathway (p<0.05).
4.3.6 Correlation analysis
4.3.6.1 Correlation between bacteria at genus and immune cytokines
As DSS induced colitis was colonic inflammation associated with mucosa,
Pearson correlation as run to investigate the possible relationship between bacteria
abundance at gene level and the expression level of inflammatory cytokines in mice
colon mucosa. As shown in the heatmap, genus Dorea, whose had greater abundance in
DSS group, was extremely positive correlated with the expression of cytokines GM-CSF,
IFN-!, IL-10, IL-1" (p<0.01) (Fig. 4.6). The four cytokines were expressed at higher
level in DSS group, followed by DSS+Nobiletin and Control group had the lowest
expression. Take genus Lactobacillus as an example for the strong negative correlation,
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the expression of IL-10 was negatively associated with the abundance of Lactobacillus.
The level of IL-10 was lowest in Control group, which had the highest abundance of
Lactobacillus in mice feces. Therefore, these results might contribute to the development
of quick diagnosis for colonic inflammation without damage.
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Figure 4.6: Heatmap showing Pearson correlation coefficients between immune cytokines
and bacteria abundance at genus level. (Red correspond to significant positive correlation
value, and blue indicate markedly inversed correlation value).
4.3.6.2 Correlation between bacteria relative abundance at genus level
Pearson correlation was run to monitor the relationship among the bacteria
relative abundance at genus level, and the r value with strong correlation was listed in the
heatmap. In our study, the abundance of Akkermansia was negatively associated with the
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abundance of Bifidobacterium, Adlercreutzia, Lactobacillus, while positively correlated
with Dorea, Dehalobacterium, Bilophila (p<0.05) (Figure 4.7). It was indicated in the
correlation heatmap that the bacteria changes were not alone. Bacteria might change in
group format, and the group member was determined by different factors.
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Figure 4.7: Pairwise genetic correlation matrix of the linear distances. Genetic correlation
was calculated from >15 million common genetic variants. Traits that have high positive
genetic correlations with each other are shown in blue. Traits that have high negative
genetic correlations with each other are shown in red.
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4.4 Discussion
Previously, our lab found that dietary nobiletin exerted anti-inflammation with
cell culture model and confirmed the effect with mice ear inflammation model [17]. In
mice colon, nobiletin was metabolized by colonic bacteria, and some of the metabolites
were even more effective than the parent compound [198]. However, the antiinflammatory effect of nobiletin with IBD associated disease was limited and the role gut
microbiota play was rare to date. As previously characterized [199, 200], murine
chemical models of colitis have many similarities to human IBD, are characterized by
cytokine dysregulation, have consistent colitis with a defined onset, and have become
useful tools to study the innate and adaptive arms of the intestinal immune response in
IBD. The mucosal immune system is the central effector of intestinal inflammation and
injury, with cytokines playing a central role in modulating inflammation [190].
Therefore, DSS induced chronic colitic model was used to explored the antiinflammatory effect of nobiletin in mice, especially focused on colonic microbiome and
systemic and mucosal immune response.
It was reported that murine DSS-induced chronic colitis had distinct cytokine
pattern [201]. The serum cytokine profile was a Th2-biased (IL-4 and IL-10) and B-cell
differentiation (IL-6 and IFN-γ) induction synergistically inflammatory profile [202],
which showed similar patterns of changes observed in local tissue (mucosa) [201]. In our
study, IL-10 and IFN-γ was upregulated in the circulation system by DSS treatment in
both serum and colonic mucosa. Besides, more cytokine changes were observed in local
site, like GM-CSF, IL-6 and IL-12. The difference might due to host difference. TNF-α
plays an important role on activation of various inflammatory cells and modulation of
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epithelial cell permeability [195]. IL-12p70 is linked with autoimmunity. It stimulated the
production of IFN-γ and TNF-α, and the significant increase of TNF-α might be
contributed by IL-12p70 in our research. Strikingly, bladder cancer, bacteria invasion at
epithelial cells and RIG-I-like receptor signaling pathway expression level was strongly
positively correlated with the level of IL-12p70 and TNF- α, indicating nobiletin
treatment might reduce its incidence. GM-CSF formation could be induced by proinflammatory cytokines, such as TNF- α and IL-1", and it has been demonstrated in
several different cell types, for example fibroblasts and endothelial cells [203, 204].
These results suggested the key role nobiletin played in modulating immune response,
indicating that nobiletin could attenuate the progress of chronic disease.
Emerging evidence points that interrupted microbiota was associated with onset
and progress of IBD [192, 205]. In addition to examining nobiletin intervention on the
disease recovery, we also accessed the impact of nobiletin on gut microbial community
composition and diversity. In this study, 500 ppm nobiletin diet trended toward recovery
from DSS-induced dysbiosis to closer to the unchallenged microbial community based on
UniFrac distance. At the meantime, the microbial composition responded dramatically to
DSS administration and nobiletin supplement.
Compared with Control and DSS group, microbiota of DSS+Nobiletin group
exhibited greater abundance of in phylum Verrucomicrobial, containing one specie
Akkermanisa Muciniphila (A. muciniphila) so far. It is a key organism at the mucosal
interface between lumen and epithelium cells due to its specific mucin degrading
property. After DSS treatment the abundance of A. muciniphila was markedly enriched,
which is consistent with others research [206-208]. However, in most human studies,
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reduced levels or depletion of A. muciniphila is observed in IBD mucosa and in fecal
samples [78]. Additional research indicates that the abundance of A. muciniphila
positively correlated with mucin level in cecum [209]. A striking observation was that the
Control group had the highest abundance of order Lactobacillales and phylum
Actinobacteria, which contains the general regarded probiotic Lactobacillus and
Bifidobacterium. These microbial results indicated thatnobiletin had the capacity to
modify the bacteria composition and provide protective effect for the gut health, though
the details about how microbiota contributed is still unknown. As such, further
investigations into the mechanism how microbiota works to improve gut health may be
necessary.
Collectively, oral administration of 500 ppm nobiletin treatment benefited mice
gut health through the modulation of microbiota and immune response. nobiletin
treatment modulated certain immune cytokines in colon mucosa and serum. Meanwhile,
microbiota should be involved in the performance of nobiletin. This study, to our
knowledge, is the first study to study the possible role of the anti-inflammation effect of
nobiletin in DSS-induced colitis.
These findings enlarged the knowledge of gut microbiota in mice microecosystem facing phytochemicals in diet. Our study provides the first line of evidence
that dietary administration of nobiletin could alter gut microbiota and their functions,
which warrants further investigation to determine its implication in human health.
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CHAPTER 5
IDENTIFY AND CHARACTERIZE BACTERIA WITH DECONJUGAION
CAPACITY FROM HUMAN FECES

5.1 Introduction
It’s documented that gut microbiota dysbiosis is associated disease, like
inflammatory bowel disease [210, 211], while diet is crucial for the dynamics of gut
microbiome. A xanthone isolated from mangosteen fruit-#-mangostin, exacerbates mice
colitis and promoted gut microbiota dysbiosis [212]. Inversely, cranberry enriched diet
ameliorated the mice colitis and modulated gut microbiota [213]. Our lab has long
outstanding interest in the interaction between dietary phytochemicals and gut
microbiota. We have observed the effect of nobiletin intervention on inflammation and
fecal microbiota composition in mice. Interestingly, nobiletin residue was at readily low
abundant compared with its metabolites in mice colon. In colon mucosa, total amount of
nobiletin metabolites (named M1, M2, M3) is about 30-fold of nobiletin. The three
metabolites (M1, M2, M3) have even stronger anti-inflammatory effect [18], indicating
that the metabolites contribute to the anti-inflammatory effect of nobiletin. Whilst, more
than 80% of nobiletin metabolites were in conjugated form in the small intestine,
suggesting that certain bacteria in the colon deconjugated the conjugates formed by Phase
II metabolism in liver [18]. Gut microbiota contributed a lot to xenobiotic metabolism,
such as Clostridium sporogenes metabolites amino acids into nine circulating

!

63!

metabolites[214], Clostridium and Eubacterium genera are commonly involved in the
metabolism of some polyphenols [215], and strain belonging to species Blautia could
hydrolyze the aryl methyl ether group from polymethoxyflavones [216]. Therefore, we
hypothesis that there’re certain strains could deconjuagte the conjugates in the colon or
feces.
In addition to the xenobiotic metabolizing capacity of gut microbiota, probiotics can
benefit host health with their secretion. Bifidobacterium infantis secretion improved
human epithelia cells (T84) barrier function by increasing the expression of tight junction
protein in vitro, and the oral treatment of bacteria secretion ameliorate gut inflammation,
increased colon barrier function in IL-10-/- mice model [137]. Conditioned medium of
Bifidobacterium longum sup infantis attenuated IL-6 production in response to IL-1"
through TLR-4 in cell H4- a human fetal small intestine epithelial cell [19].
In this study, we will isolate and characterize the bacteria from human feces with
nobiletin metabolites deconjugation capacity. The bioactivities of the isolated bacteria
secretion will be studied also, including anti-inflammation and anti-cancer capacity.
5.2 Material and Methods
5.2.1 Bacteria isolation
Fresh fecal sample from a healthy male donor (27-32 years old) was collected and
homogenized with sterilized peptone water (1:10). Fecal bacteria were collect after
centrifugation (200 g ×5 min, 4 ℃) to remove food residues. Then serial diluted fecal
microbiota streaked on Gifu anaerobic agar (GAM, Nissui Pharmaceutical Co., Tokyo,
Japan) and cultured in an anaerobic cabinet (Whitley A35 anaerobic workstation, Don
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Whitley Scientific) under an atmosphere of 5% CO2, 10% H2, and 85% N2 at 37 °C for
48 h. Single colonies were incubated with small intestine content (10 mg/mL) collected
from mice fed with dietary nobiletin. After 48 h fermentation, the supernatant and
bacteria were collected for future analysis.
5.2.2 Determine the biotransformation potential of isolated colonies
200 'L fermentation supernatant was extracted with double volume of ethyl
acetate for three times. Pooled ethyl acetate fractions were dried under speed vacuum
condition and re-dissolved in 50% acetonitrile for HPLC analysis (Model 2000, Agilent
Technologies, USA) on an Amino acid C18 column (250 mm × 4.6 mm, 5 µm, Agilent
Technologies, USA) at a flow rate of 0.8 mL/min. The linear gradient elution condition
was: started with 75% mobile phase A (5% ACN/water, v/v)/25% mobile phase B (100%
ACN) (v/v) for 5 min, then processed to 100% B over 20 min, and held at 100% B for 5
min. The elution was monitored at UV length 326 nm [217]. Nobiletin (Quality
Phytochemicals LLC, Edison, NJ, USA) and its free form metabolites (M1, M2, and M3,
synthesized within our lab with purity≥98%), were used as external standards for
nobiletin and its metabolites identification and quantification.
5.2.3 16S rRNA gene sequencing and phylogenetic analysis
Strain Isolate G7 was isolated from the fecal sample, which showed
deconjugation potential. 16S rRNA gene sequencing was applied for bacteria
identification. Partial 16S rRNA gene was amplified by PCR with primers 27F (5′AGAGTTTGATCMTGGCTCAG-3′) and 1492R (5′-GGYTACCTTGTTACGACTT-3′)
[216], and sequencing was done by the sequencing service at GENWIZ (NJ, USA). The
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16S rRNA sequence was analyzed with the BLAST tool in National Center for
Biotechnology Information (NCBI) to identify bacterial species based on sequence
similarity[218]. Phylogenetic trees were constructed with neighbor-joining method with
MEGA 7 program [219].
5.2.4 Isolate G7 secretion collection
Stored bacteria Isolate G7 was subcultured on MRS agar (Difco Laboratories, MI,
USA) containing 0.5 g/L L- cysteine (Sigma- Aldrich, St. Louis, MO, USA) in anaerobic
condition at 37 °C for 2 days. Single colony was inoculated in fresh MRS broth overnight
and the OD600 nm was adjusted to 0.5. Then, the adjusted Isolated G7 inoculate was
inoculated with MRS broth (1: 100, v:v) supplemented with small intestine content from
mice fed with nobiletin (final concentration 10 mg/mL), and incubated at 37 °C in
anaerobic condition for 48 h. Fermentation samples were collected every 12 h and filtered
through 0.22 um filter to obtain sterile isolate G7 secretion. Samples collected at different
time point were stored at -20 °C for future treatment.
5.2.5 Anti-inflammation assay with RAW 264.7 cells
RAW 264.7 cells purchased from the American Type Culture Collection (ATCC,
Rockville, MD, USA) were cultured in Roswell Park Memorial Institute (RPMI) 1640
media supplemented with 10% heat-inactivated foetal calf serum (FBS) (Medistech,
Herndon, VA, USA), 100 units/mL of penicillin and 0.1 mg/mL of streptomycin (SigmaAldrich, St. Louis, MO, USA) at 37 °C with 5% CO2 and 95% air. Cells were seeded
into 96-well plate (1×106 cells/mL). After 24 h attachment, cells were stimulated by
incubation in a medium containing100 ng/mL lipopolysaccharides (LPS) and Isolate G7
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secretion (7.5%) collected at different time were added together with LPS. Cells were
treated with7.5% MRS as the vehicle control and cells treated with 7.5% MRS without
the presence of LPS as the blank control.
Nitric oxide production by RAW 264.7 cells was determined as nitrite
concentration in the culture medium according to the Griess reaction [220]. The culture
medium of the control and treated cells was collected and mixed with an equal volume of
Griess reagent (1% sulphanilamide in 5% phosphoric acid and 0.1%
naphthylethylenediamine dihydrochloride in water). Absorbance of the mixture was read
at 550 nm with microplate reader (Dynatech MR-7000, Dynatech Laboratories, Chantilly,
VA). The Nitric oxide production was normalized by MTT results.
The MTT assay is based on the reduction of the tetrazolium salt, 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), by actively growing cells.
After cells being treated for 24 h, cell culture medium was replaced with100 'L MTT
solution (1.0 mg/mL RPMI) and cells were incubated for 2 h. Thereafter, dumpling the
culture supernatant, 100 'L DMSO was added into each well and the plate was gently
agitated to dissolve crystal MTT. Absorbance was measured at 540 nm, with microplate
reader (Dynatech MR-7000, Dynatech Laboratories, Chantilly, VA). DMSO was used as
a negative control. Normalized nitric oxide production = OD550 nm/OD540 nm. For cell
cytotoxicity, active cells were detected by MTT assay. Cell viability (%)= (OD of
treatment group/OD of control group)*×*100.
5.2.6 Analysis of cell viability, cell cycle and cell apoptosis
Human colon cancer cell HCT 116 (ATCC, Manassas, VA, USA) were cultured
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in RPMI-1640 media supplemented with 5% heat-inactivated FBS and antibodies (100
units/mL penicillin and 0.1 mg/mL streptomycin) at 37 °C with 5% CO2 and 95% air.
Assays for cell viability, cell cycle and apoptosis were conducted as we previously
described [221-223]. In brief, cell HCT116 were seeded in 96-well plates (2 ×104
cells/mL). After 24 h, cells were treated with 7.5% isolate G7 secretion for 24 h, and the
cell viability was quantified by MTT assay. HCT116 were seeded in 6-well plates for cell
cycle and apoptosis analysis (5×104 cells/mL). After 24 h incubation for cell attachment,
cells were treated with 7.5% isolate G7 secretion. After 24 h treatment, floating cells in
medium were harvested and combined with attached cells that were detached by brief
trypsinization. Then cell pellets were washed with 1 mL of ice-cold PBS and subject to
cell cycle and apoptosis analysis by flow cytometry as we described previously [221223]. 7.5% MRS treatment was used as control.
5.2.7 Immunoblotting
Whole cell lysate was prepared as previously described [223, 224]. RAW 264.7
cells were seeded in 10-cm culture dishes. After 24 h of incubation, RAW 264.7 cells
were treated with 1.0 µg/mL LPS alone or with 15% isolate G7 secretion. HCT116 cells
were treated with 7.5% isolate G7 secretion only. The same percentage of MRS was used
as control. After 24 treatment, the cells were harvested and extracted with RIPA lysis
buffer (Boston Bioproducts, Ashland, MA, USA) containing 1% protease inhibitor
cocktail (Boston Bioproducts). The homogenates were centrifuged at 12,000×g for 20
min at 4 °C. Protein concentrations were determined with the BCA method (Pierce,
Rockford, IL, USA). The cell lysates were further subjected to Western blotting analysis
as previously described [223, 224]. Antibodies for iNOS, COX-2, Bcl-2, cleaved-PARP,
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cyclin D1, cyclin E, CDK4, CDK6 and p21 were obtained from Cell Signaling
Technology (Beverly, MA, USA). Antibody for β-actin was purchased from SigmaAldrich.
5.2.8 qRT-PCR
qRT-PCR was performed as previously described [225]. Total RNA was extracted
from HCT116 cells with Trizol Reagent (Ambion) according to the manufacturer’s
instructions. Total RNA (2 (g) was converted to cDNA using a High Capacity cDNA
Reverse Transcription kit (Applied Biosystems) according to manufacturer’s instructions.
The qRT-PCR was carried out with Applied Biosystems ViiA 7(TM) Real Time PCR
System (Life Technology) with Maxima SYBR-green Master Mix (Thermo Fisher
Scientific). The sequences of human colon cell specific primer (Thermo Fisher Scientific)
were listed in Table 5.1. Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) was used
as an internal control. The copy number of each transcript was calculated with respect to
the Gapdh copy number, using the 2-

ΔΔCT

method [226].

Table 5. 1 Sequence of primers used in qRT-PCR for Wnt signaling
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Gene

Forward

Reverse

Gapdh

AGGTCGGTGTGAACGGATTTG

TGTAGACCATGTAGTTGAGGTCA

c-MYC

TGAAGTTCACGTTGAGGGG

AGAGCTCCTCGAGCTGTTTG

Cyclin D1

AGAGGCGGAGGAGAACAAAC

GGCGGATTGGAAATGAAC

AXIN2

TGCATCTCTCTCTGGAGCTG

ACTGACCGACGATTCCATGT

CDC-2

CGCCCTTTCCTCTTTCTTTC

ATCGGGTAGCCCGTAGACTT
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5.2.9 Statistic analysis
Data were presented as means ± standard deviation (S.D.) for the indicated
number of independently performed experiments. All statistical analyses were performed
using SPSS. Unpaired student's t-test was used to assess the mean difference between two
groups. A p-value<0.05 was considered statistically significant.
5.3 Results and Discussion
5.3.1 Strain Isolate G7 isolation
Humans have co-developed with trillions of microorganisms living in and on
human body, whose genomes extend our metabolic capacity beyond those encoded by
human genome. Xenobiotic metabolism is one of the major influence of gut microbiota
on host, which will affect the bioactivity, bioavailability and toxicity of xenobiotics.
Deconjugation is one of the most common reaction type, which contributed to the antiinflammation effect of nobiletin in mice. As we mentioned before, free form of
metabolites of M1, M2 and M3 has way stronger anti-inflammation and anti-cancer effect
than nobiletin [113, 114]. Here, we wanted to isolate bacteria with deconjugation
capacity.
From the diluted fecal samples, 46 single colonies were isolated and incubated
with small intestine content from mice fed with nobiletin to determine the deconjugation
activity. After 48 h fermentation, supernatants extracted by ethyl acetate were loaded into
HPLC. For nobiletin metabolite conjugates incubated with Isolate G7, peaks for free form
nobiletin metabolites M1, M2 and M3 appeared (Figure 5.1), indicating that Isolate G7
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could secret enzyme to release glucose or sulfate group from the conjugates formed by
Phase II metabolism. Then, Isolate G7 was successfully subcultured on GAM plates
anaerobically without losing deconjugation activity.

M1

mAU

100

M2
M3
Nobletin

50

SI content
+ Isolate G7
SI content

0
10

15
Retention time/min

20

Figure 5. 1 Chromatograph for small intestine content from mice fed with nobiletin
fermented with the presence or absence of Isolate G7.
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5.3.2 Strain Isolate G7 identification
To identify the bacteria Isolate G7, its partial16S rRNA gene sequence was
obtained by Sanger sequencing. After blasting in NCBI, gene sequence was most closely
related with Bifidobacterium Pseudocatenulatum DSM20438 and IPLA36007, showing
98% similarity. Other strains in the family Bifidobacteriaceae and genus
Bifidobacterium, particularly Bifidobacterium catenulatum DSM16992, Bifidobacterium
adolescentis Reuter 1963, Bifidobacterium angulatum DSM20098, Bifidobacterium
dentium DSM20436, Bifidobacterium breve DSM20213 and Bifidobacterium bifidum
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ATCC29521, also showed high sequence similarity (> 90% similarity) to the isolated
bacterium (Figure 5.2). Therefore, the isolated G7-metabolizing anaerobic bacterium was
identified as Bifidobacterium pseudocatenulatum G7. Bifidobacterium
pseudocatenulatum IPLA 36007, isolated as from human feces, exhibited the capability
of releasing aglycones from soy isoflavone glycosides[227, 228]. There’re some other
species showed the deconjugation capacity, like Bifidobacterium animalis [229],
Bifidobacterium breve[230], Bifidobacterium angulatum, Bacteroides thetaiotaomicron,
and Eubacterium siraeum[231].
Bifidobacterium pseudocatenulatum IPLA36007

70 Isolate G7
100 Bifidobacterium pseudocatenulatum DSM20438

40
97
66
100

54
99

Bifidobacterium pseudocatenulatum CECT7765
Bifidobacterium pseudocatenulatum D2CA
Bifidobacterium catenulatum DSM 16992
Bifidobacterium angulatum DSM 20098
Bifidobacterium adolescentis Reuter 1963
Bifidobacterium dentium DSM 20436
Bifidobacterium breve DSM 20213
Bifidobacterium infantis ATCC 15697
98 Bifidobacterium longum subsp. longum JCM 1217
Bifidobacterium bifidum ATCC 29521
AAlloscardovia omnicolens DSM 21503
AAeriscardovia aeriphila T6

99
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Figure 5.2 Phylogenetic tree of Isolate G7 with strains belong to the same family.
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5.3.3 Anti-inflammatory effect of Isolate G7 secretion
In addition to xenobiotic metabolizing capacity, species Bifidobacterium
pseudocatenulatum is generally regarded as probiotic. Several researches indicated that
oral administration of Bifidobacterium pesudocatenulatum could benefit host health [232235]. However, research on how probiotic benefit host health is till overlooked. Colon is
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the niche where most bacteria grow and colonize. The biofactors released during bacteria
growth might improve host health.
Macrophages is a major component of the mononuclear phagocyte system, like
blood monocytes, and tissue macrophages. They play a critical role in the initiation,
maintenance, and resolution of inflammation [236]. Therefore, we tested the antiinflammation effect on macrophages, which is the common immune cells. From the
Figure 5.3a, it’s obvious that Isolate G7 secretion collected at different time points
showed marginal effect on cell viability (>93% cell survived), indicating that Isolate G7
secretion has no toxic effect on macrophages. Cell inflammation induced by LPS was
significantly inhibited by bacteria secretion, as shown by the reduced production of nitric
oxide. The anti-inflammation effect showed a fermentation time dependent response,
indicating that most effective components was secreted during the whole 48 h
fermentation time. At the time 48 h, the nitric oxide produced was as low as about 6.5%,
which was 92.7% at time 0 h.
To make clear the pathway involved in the anti-inflammation effect, we checked
key protein expression. Pro-inflammatory enzyme iNOS catalyzes the oxidative
deamination of L-arginine to generate NO, which is a critical inflammatory mediator.
Overproduction of NO can further cause the structural modification of DNA and
mutagenesis [237]. Since iNOS and its downstream products play key roles in the
occurrence of chronic inflammatory diseases including colon cancer, iNOS and related
signaling molecules have become critical targets for anti-inflammation and anticancer
remedy [238]. Enzyme COX-2 is a rate-limiting step for Prostaglandin E2 synthesis,
which is produced by macrophages and contributes to vasodilation, pain and fever [239].
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Comparing with the negative control group (without LPS and Isolate G7 secretion
treatment), LPS treatment stimulated the production of proteins iNOS and COX-2 with a
dark bold band. While the expression of protein iNOS and COX-2 were almost depleted
when treated with Isolate G7 secretion (48 h), with iNOS downregulated to 0.001 and
COX-2 was decreased to 0.14 of the positive control group (Figure 5.3b). Both enzyme
iNOS and COX-2 are downstream key proteins in NF-$B pathway, suggesting that
isolate G7 secretion could interrupt NF-$B pathway in macrophages. Therefore, isolate
G7 could inhibit LPS-induced inflammation on macrophages by blocking the NF-$B
pathway.
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Figure 5.3 Anti-inflammation effect of isolate G7 secretion on LPS stimulated
inflammation on RAW 264.7. (a) Cytotoxicity and nitric oxide production of Isolate G7
secretion treatment obtained at different fermentation time. (b) The expression of
enzymes iNOS and COX-2 with or without isolate G7 secretion treatment.
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5.3.4 Anti-cancer effect of Isolate G7 secretion
The connection between inflammation and tumorigenesis is well-established and
in the last decade has received a great deal of supporting evidence from genetic,
pharmacological, and epidemiological data. Inflammatory bowel disease is an important
risk factor for the development of colon cancer[240]. Here, we studied the anti-cancer
effect on human colon cancer cell HCT116. After cells treated with bacteria secretion for
24 h, cell viability was reduced dramatically, specifically for sample collected at 24 h
fermentation time, which can be lower than 40% (Figure 5.4), suggesting that isolate G7
secretion could inhibit cancer cell proliferation effectively.
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Figure 5. 4 Cell viability of HCT116 after treated with Isolate G7 secretion obtained at
different fermentation time.
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Dysfunction in the physiological pathways of programmed cell death may
promote proliferation of malignant cells, and correction of such defects may selectively
induce apoptosis in cancer cells. Cell apoptosis is an effective way to lead cancer cell
death. Isolate G7 secretion treatment markedly increased both early and late apoptosis for
cell HCT116 (p<0.01), and the total apoptotic cells with treatment was about 3-fold of the
control group (Figure 5.5a). To confirm this finding, we checked the key protein
expression related with cell apoptosis. Protein Bcl-2 is an anti-apoptotic protein[241],
whose expression was downregulated to 66% comparing with control group (Figure
5.5b). Protein Cleaved-PARP is named damaged protein sensor, and hyperactivation of
the PARP pathway may be exploited to selectively kill cancer cells. During apoptosis, the
presence of the 89-kDa PARP cleavage fragment is considered a marker of cells that have
undergone apoptosis[242, 243]. In Figure 5.5b, it’s obvious that protein Cleaved PARP
expression was upregulated by 42% with isolate G7 secretion treatment. Here, we could
point out that the isolate G7 secretion treatment could induce human colon cancer cell
HCT116 apoptosis.
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Figure 5.5 (a) Effects of Isolate G7 secretion obtained at 48h fermentation time on cell
apoptosis. (b) Effects of Isolate G7 secretion obtained at 48h fermentation time on cell
apoptosis-related signaling proteins.
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Except cell apoptosis, cell cycle progression plays essential roles in cancer. In
normal cells, cell cycle is strictly regulated by a series of signaling pathways. However,
in cancer, this regulatory process is often malfunctioned due to genetic mutations [244].
Thus, induction of cell cycle arrest is an effective strategy to control cancer. Therefore,
we tested the cell population at different cell cycle stages after treated with Isolate G7
secretion. Cell cycle is divided into three phases, G0/G1 phase, S phase and G2/M phase.
With Isolate G7 secretion treatment, cell population was arrested at G2/M phase
significantly (p<0.05) (Figure 5.6a). The effect of Isolate G7 on the expression of several
cell cycle related proteins was monitored also. Cyclins and cyclin-dependent kinases
(CDKs) are two important classes of proteins that regulate the cell cycle progression.
Misregulated cyclins and CDKs may stimulate abnormal cell proliferation and genomic
and chromosomal instability. The transition of cell cycle from G1 to S phase is mainly
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driven by cyclin D-CDK4/6 and cyclin E-CDK2 complexes. CDK inhibitors, such as p21
can arrest cell growth by holding the cell cycle at the G1/S transition point [221]. In
figure 5.6b, protein cyclin D1, cyclin E, CDK4, CDK6 and P21 were all misregulated by
isolate G7 secretion, suggesting that isolate G7 secretion could modulate cell cycle and
contribute to the lower active cell number.
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Figure 5. 6 (a) Effects of Isolate G7 secretion obtained at 48h fermentation time on cell
cycle. (b) Effects of Isolate G7 secretion obtained at 48h fermentation time on cell cyclerelated proteins in human colon cancer cell HCT116.
Overactivation of Wnt signaling is a hallmark of colorectal cancer. Wnt pathway
is a key regulator of both the early and the later, more invasive, stages of CRC
development[245]. In CRC, aberrant activation of the Wnt signaling pathway is a central
oncogenic driver in 90% of patients, mostly resulting from mutations in the adenomatous
polyposis coli gene[246]. CDC-2, Cyclin D, c-MYC and AXIN2 are all genes involved in
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Wnt pathway. All these genes were remarkably downregulated when treated with isolate
G7 secretion (Figure 5.7). The deactivation capacity of Wnt signaling pathway proved the
anticancer effect of isolate G7 secretion. Simply, we could conclude that isolate G7
secretion has strong anti-inflammation effect by promoting cell apoptosis, arrest cell
cycle and deactivate Wnt pathway.
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Figure 5.7 Effects of Isolate G7 secretion obtained at 48h on the gene expression
associated with Wnt signaling pathway in cell HCT116.
5.4 Conclusions
After oral administration of xenobiotics, it will interact with gut microbiota in
vivo. Xenobiotic could be metabolized by specific bacteria and influence its bioactivities.
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Besides, xenobiotic could modify the gut microbiota, which may influence host health.
For the strong anti-inflammation effect of nobiletin, we found that bacteria Isolate G7 in
mice colon could release the free form of M1, M2 and M3 which contributed to the antiinflammation effect. Besides, the Isolate G7 is comes from species Bifidobacterium
pseudocatenulatum, which is a probiotic. Isolate G7 secretion has strong antiinflammation effect by blocking the NF-$B pathway. What’s more, Isolate G7 secretion
exerted distinguished anti-cancer potent by promoting cancer cell apoptosis, arrest cell
cycle at G2/M phase, and downregulate the Wnt signaling pathway. Therefore, we can
infer that the interaction between nobiletin and gut microbiota contributed to the antiinflammation effect of nobiletin. Probiotic isolate G7 has the potential to be a functional
food to benefit human gut health.
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CHAPTER 6
ENCAPSULATION OF BIFIDOBACTERIUM PSEUDOCATENULATUM G7 IN
GASTROPROTECTIE MICORGELS: IMPROVEMENT OF CELL VIABILITY
UNDER SIMULATED GASTROINESTINAL CONDITIONS

6.1 Introduction
The human gastrointestinal tract (GIT) typically contains hundreds to thousands
of different bacterial species, forming a complicated microbial ecosystem [2]. The genus
Bifidobacterium is one of the most common bacteria in the feces (3.2 %) and cecum
(5.2 %) of humans [247-249]. Bifidobacterium species are regarded as probiotics due to
their potential health benefits and have been generally recognized as safe (GRAS) by the
US government [250]. There are more than 50 species belonging to the genus
Bifidobacterium, with Bifidobacterium pseudocatenulatum (B. pseudocatenulatum) being
one of the most dominant species.
As a probiotic, B. pseudocatenulatum has been studied for its efficacy in the
prevention and treatment of a broad spectrum of animal and/or human gastrointestinal
disorders. It has been reported to attenuate abnormal vascular function in obese mice [8],
to partially restore neuroendocrine function in obese mice [251], and to reduce
inflammation in mice with cirrhosis [252]. However, probiotics have to reach their site
of action at a sufficiently high level before they can exhibit their potential health benefits.
Unfortunately, environmental challenges encountered in the human GIT, such as gastric
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acids, bile salts, and digestive enzymes, have limited the application of probiotics in vivo
[253].
Encapsulation of probiotics in colloidal delivery systems can improve the shelf life
and viability of probiotics during storage and in the GIT [139-141]. Encapsulation of
Lactobacillus casei 01 in alginate-starch beads improved cell viability during freezedrying and storage [142]. Encapsulation of B. longum in alginate microgels coated with
chitosan improved their survival during passage through a simulated GIT [139].
However, there are few studies showing that colloidal delivery systems can successfully
preserve the viability of probiotics after 2 hours’ exposure to gastric conditions [139,
143]. The main reason for the poor gastric stability of probiotics encapsulated in
microgels is that hydrogen ions (H+) can easily diffuse through the hydrogel network and
inactivate the encapsulated bacteria. Previously, we prepared alginate microgels loaded
with an antacid agent, Mg(OH)2, that could neutralize hydrogen ions when they entered
the microgels and thereby maintain a neutral internal pH even when they were dispersed
in acidic gastric fluids [144]. These antacid microgels may therefore be particularly
useful for increasing the cell viability of probiotics for oral delivery.
B. pseudocatenulatum G7 (BPG7) has been isolated from healthy human feces in
our laboratory and shown to have strong anti-inflammation and anti-cancer activities
(data not shown). The availability of an effective oral delivery system for this potent
probiotic that would protect it throughout the GIT would be highly advantageous for
commercial applications [254]. In this study, we encapsulated BPG7 in alginate
microgels loaded with two different kinds of antacids, either Mg(OH)2 or CaCO3. Both
Mg(OH)2 and CaCO3 are widely used food-grade antacids, which are insoluble at neutral
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and basic pH but dissolve at acidic pH thereby releasing hydrogen ions (OH-). We
hypothesized that these antacid microgels would maintain an internal neutral pH under
acidic gastric conditions so as to enhance the viability of the probiotic in the
gastrointestinal tract. The results obtained from the current study should provide valuable
information for optimizing the performance of probiotic-loaded delivery systems for
applications in functional foods and beverages.
6.2 Material and methods
6.2.1 Bacteria propagation and general growth conditions
The probiotic (BPG7) was stored at -80 oC in deMan, Rogosa, Sharpe (MRS)
broth (Difco Laboratories, Sparks, MD) containing 50% glycerol (Sigma, St Louis, MO,
USA). After growing on a MRS agar plate at 37 oC for 48 h, a single colony was selected
and propagated in fresh 40 mL MRS for 24 h, anaerobically. Anaerobic conditions were
maintained using an anaerobic chamber with an airlock (82% N2, 10% CO2 and 7% H2;
Whitley A35 Anaerobic Workstation, Microbiology International, Frederick, MD).
6.2.2 Probiotic Microencapsulation
Cells were harvested by centrifugation at 4000 g for 10 min at 4 oC and then
washed twice with sterile peptone water. The washed cells were re-suspended in 20.0 mL
sterile deionized water. BPG7-loaded microgels were prepared by mixing the bacteria
with 2% sodium alginate solution in the absence of presence of an antacid agent (either
Mg(OH)2 or CaCO3) (1:1, v/v). As shown in Figure 1, the polymeric matrix was agitated
to uniformly distribute the bacterial cells throughout the mixture. The mixture was left to
stand for 5 min to allow any dissolved air to leave the solution prior to microgel
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preparation using an automated encapsulation device (Büchi B-390 Encapsulator, Flawil,
Switzerland). An injection nozzle with a diameter of 200 µm was used and standard
operating conditions were utilized: vibration frequency = 800 Hz, electrode potential =
800 V, and driving pressure = 500 mbar. The microgels were collected in 60 mL of 10%
calcium chloride solution (Sigma, St Louis, MO, USA). The microgels were then
vacuum-filtered and rinsed with sterile deionized water (200 mL).
6.2.3 Surface potential characterization of encapsulated calcium alginate microgels
The surface potential ( -potential) of the microgels was determined using an
electrophoretic light scattering device (Zetasizer Nano ZS, Malvern Instruments,
Worcestershire, UK). For each sample, filtered microgels (~0.1 g) were re-suspended in
appropriate pH-adjusted solutions prior to measurements to avoid multiple scattering
effects. Specifically, phosphate buffer (5 mM, pH 7.0) was used for the dilution of initial
and small intestine samples, while acidified distilled water (pH 2.5) was used for dilution
of the stomach samples.
6.2.4 Particle size characterization of encapsulated calcium alginate microgels
The particle size distribution of all the samples was measured using a static light
scattering instrument (Mastersizer S, Malvern Instruments, Worcestershire, UK). Again,
initial and small intestine samples were diluted in phosphate buffer (5 mM, pH 7.0) while
stomach samples were diluted in acidified distilled water (pH 2.5) to avoid multiple
scattering effects. The particle sizes are reported as the surface-weighted mean diameter
(d43).
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6.2.5 Cold-stage scanning electronic microscopy (cryo-SEM)
Microgels were fixed by immersion in 2.5% (v/v) glutaraldehyde in 0.5 M sodium
cacodylate-hydrochloric acid buffer (pH 7.2) for 1 h at room temperature. The fixed
samples were then washed three times in deionized water. The alginate microgels were
then placed on an aluminum SEM stud and a second stub was placed on top to create a
cap on top of the alginate microgels. This sandwich was then plunge frozen in liquid
nitrogen. Once frozen, the aluminum stubs were quickly pulled apart, which fractured the
microgels. The two aluminum stubs were then placed in a vacuum lyophilizer and
completely dried overnight. The next morning the fractured and dried alginate microgels
were mounted to carbon tape on a SEM stub and sputter coated with 6 nm of Au/Pd
(80/20). The mounted and coated specimens were examined and digitally imaged at
various magnifications using a scanning electron microscope (FEI Quanta 200 MKII
FESEM, FEI Company, Hillsboro, Oregon, USA).
6.2.6 Confocal scanning laser microscopy (CLSM)
Cell viability and distribution were characterized using confocal scanning laser
microscopy (CLSM). The probiotic was labelled with fluorescent molecular probes using
a LIVE/DEAD BacLight Bacterial Viability Kit (Thermo Fisher Scientific, MA, USA).
Dye SYTO 9 is a green-fluorescent nucleic acid stain for both live and dead cells,
whereas propidium iodide (PI) is a red-fluorescent nucleic acid stain that only interacts
with cells that have damaged membranes, leading to a reduction in the SYTO 9
fluorescence signal. Therefore, live bacteria fluoresce green, while dead bacteria
fluoresce red. Equal volumes of the SYTO 9 and PI dyes were mixed together. Then, 3
µL of this dye mixture was added to 1 mL microgel solution and incubated in the dark for
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15 min at room temperature prior to visualization with CLSM [255]. Images were
obtained with a 20-objective lens (Nikon D-Eclipse C1 80i, Nikon, Melville, NY, USA).
For the SYTO 9 dye, an excitation wavelength of 488 nm was used and an emission
wavelength of 590 nm/50 nm. For the PI dye, an excitation wavelength of 488 nm was
used and an emission wavelength of 650 nm/LP. The confocal fluorescent images were
analyzed using image analysis software (NIS-Elements, Nikon, Melville, NY, USA).
6.2.7 Enumeration of viable cells
To determine viable cell counts of encapsulated bacteria, alginate microgels (0.10 g)
were suspended in 9.9 mL of 10% sodium citrate dihydrate solution (pH 8.2; Fisher,
Fairlawn, NJ, USA) followed by mixing for 10 min at room temperature to dissociate
them. After serial dilutions of the dissociated microgels (10-2–10-5), the number of
surviving cells was determined by plate culture on MRS agar in duplicate and
anaerobically incubated at 37 °C for 48 h. All the samples were counted initially, after the
simulated stomach phase, and after the simulated stomach and small intestinal phase.
6.2.8 Simulated gastrointestinal fate of microgels
Samples with the same concentrations of free or encapsulated BPG7 cells and the
same total volumes were prepared by diluting the original samples with buffer solution (5
mM PBS, pH 7). The samples were then passed through an in vitro GIT model that
simulated the stomach and small intestine phases. Specifically, simulated gastric fluids
(SGF) was prepared by adding sodium chloride (2 g) and 6 M hydrochloric acid (7 mL)
into one-liter of distilled water and then filter sterilized. The simulated intestinal fluids
(SIF) was prepared by dissolving calcium chloride (0.25 M) and sodium chloride (3.75
M) in phosphate buffer (5 mM PBS, pH 7). A bile salts solution was prepared by
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dissolving 1.5 g porcine bile extract in 28 mL phosphate buffer (5 mM PBS, pH 7), and
3.5 mL of the bile salts solution was added to each intestinal phase. All the simulated
stock solutions were subjected to autoclaving before the experiments.
Free and encapsulated BPG7 cells were sequentially added to SGF (45 mL, pH
adjusted to 2.5) for 2 h, and then incubated with SIF (45 mL, pH adjusted to 7.0) for 2 h.
All the incubation experiments were carried out in an anaerobic chamber set at 37 °C.
Dilutions (10-0–10-5) of the released cells were plated on MRS agar for samples collected
initially, after 2 h exposure to a simulated gastric phase, or after 4 h exposure to
simulated gastric and then intestinal phases. Then MRS plates were incubated
anaerobically for 48 h at 37 °C for viable cell counting.
6.2.9 Statistical analysis
Experiments on the physicochemical characteristics of the microgels were repeated
in duplicate. Experiments on viable cells counts were repeated at least six times
independently. All values are expressed as mean ± standard deviation (SD) unless stated
otherwise. The difference among samples were analyzed by one-way ANOVA with
significance level of p < 0.05.
6.3 Results and Discussion
6.3.1 Particle size analysis
Alginate is an anionic polysaccharide that has been widely used for the
microencapsulation of probiotics because of its ability to form microgels using a simple
injection process. Two different antacid agents, either Mg(OH)2 or CaCO3, were coencapsulated with the probiotics inside the alginate microgels to enhance their viability
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during gastrointestinal transit (Figure 6.1). A series of controls was also studied: alginate
microgels containing no antacids or probiotics; Mg(OH)2-loaded microgels with no
probiotics; and, CaCO3-loaded microgels with no probiotics. Changes in the particle size
of the microgels were then determined as they passed through various stages of the
simulated GIT. Incubation under oral conditions was not simulated in the current study
because the short duration and neutral pH conditions in the human mouth would not have
been expected to impact cell viability.
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Figure 6.1 Schematic diagram of delivery systems fabrication containing probiotic loaded
beads with or without buffer agent encapsulation.
The general shape of the particle size distribution of all the microgels remained
fairly similar throughout the entire GIT (Figure 6.2), suggesting that they retained their
overall integrity when exposed to upper gastrointestinal conditions. There was a slight
decrease in the mean particle diameter (d43) for all the samples after exposure to the
simulated stomach phase, which has been previously attributed to a reduction in the
electrostatic repulsion between the anionic alginate chains when the carboxyl groups
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become partially protonated under acidic conditions. Interestingly, the CaCO3-loaded
microgels were initially larger (665 µm) than the Mg(OH)2-loaded ones (540 µm). This
may have been because the initial alginate-CaCO3 solution had a higher viscosity than the
alginate-Mg(OH)2 solution before injection (data not shown). This may have been
because some of the solid CaCO3 particles partially dissolved and released a few calcium
ions (Ca 2+) that cross-linked the alginate and increased the solution viscosity.
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Figure 6. 2 Particle size distribution of different delivery systems after exposure to
successive GIT stage: (a) Control beads (b) CaCO3-loaded beads and (c) Mg(OH)2loaded beads.
6.3.2 Surface potential analysis
The electrical characteristics of the microgels were also determined during the
simulated GIT process. All the microgels initially had a strong negative charge of around
-25 mV (Figure 6.3), which can be attributed to the presence of anionic carboxylic acid
groups (–COO- ) from the alginate molecules being present at the hydrogel surfaces. An
appreciable reduction in the magnitude of the

-potential occurred for all the microgels

after exposure to the simulated stomach phase. This effect is due to the fact that the
simulated gastric fluids have a low pH and high ionic strength, which reduced the
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10000
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ionization of the anionic charged groups and caused electrostatic screening effects. This
result is consistent with the observed shrinkage of the microgels under simulated stomach
conditions, as mentioned in the previous section. After exposure to the small intestine
phase, all the microgels again had relatively high negative charges. This was due to the
deprotonation of the carboxyl groups on the alginate molecules under simulated intestine
conditions (pH 7), as well as the presence of anionic species such as bile salts. Overall,
all the antacid-loaded microgels had fairly similar charge characteristics throughout the
simulated GIT, indicating that encapsulation of the antacids did not change their surface
potentials.
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Figure 6. 3 Electrical properties of the particles in different delivery systems measured
after exposure to different GIT stages.
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6.3.3 Cryo-SEM for hydrogel beads with presence or absence of antacid agent
Cryo-SEM was used to probe the internal structure of fractured alginate microgels
in the absence or presence of antacid agents (Figure 6.4). Cryo-SEM allows detailed
observation of microgels in the frozen hydrated state. Compared with conventional SEM,
potential artifacts like shrinkage produced by dehydration and fixation are avoided using
cryo-SEM [256]. To study their inner structure, alginate microgels were cracked by cryofracturing and then the cracked surfaces were visualized by SEM. The probiotics were
clearly observed at the surfaces of the antacid-free microgels (Figure 6.4a). Both
probiotics and irregular shaped particles (presumably antacid crystals) were observed in
the probiotic-loaded microgels containing Mg(OH)2, which were indicative of the
presence of antacid crystals (Figure 6.4b). Probiotics were visible in clusters at the
surfaces of the probiotic-loaded microgels containing CaCO3, which appeared to have a
highly variegated surface morphology (Figure 6.4c).
In the absence of probiotics, the surfaces of the antacid-free microgels appeared
smoother than in the two antacid-loaded microgels (Figure 6.4d-f). The irregular surfaces
of the antacid-loaded microgels was probably because of the presence of antacid crystals
embedded inside them. The SEM images suggested that the size of the Mg(OH)2 crystals
were considerably smaller than those of the CaCO3 crystals. In addition, the structure of
the hydrogel network in the microgels appeared to be different when they contained
different antacids. This effect might have been caused by the presence of different ions
(magnesium versus calcium) that altered the cross-linking between the alginate chains in
the hydrogel network [257].
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Figure 6. 4 Cold-stage scanning electron microscopy (cryo-SEM) of calcium alginate
microcapsules. (a) Fractured alginate micorgels with bacteria. (b) Fractured
microcapsules with bacteria with the presence of antacid agent-Mg(OH)2. (c) Fractured
microcapsule with bacteria with the presence of antacid agent-CaCO3. (d) Fractured
structure of calcium alginate microgels. (e) Fractured structure of alginate microgels
filled with antacid agent-Mg(OH)2 without bacteria. (f) Fractured structure of alginate
microgels loaded with antacid agent- CaCO3 without bacteria. Magnification is indicated
individually on data bar at the bottom of micrograph.
6.3.4 Viability of encapsulated BPG7 under simulated digestion
Previous studies have shown that probiotics tend to be inactivated during their
passage through the upper GIT and therefore do not reach the colon intact [258].
Therefore, we examined the impact of microgel encapsulation on cell viability when
exposed to simulated GIT conditions. BPG7 cells encapsulated in alginate microgels in
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the absence or presence of antacids (Mg(OH)2 or CaCO3) were subjected to simulated
stomach or stomach/small intestine conditions [259]. The level of viable cells that
survived was measured before and after exposing them to simulated GIT conditions
(Figure 6.5 and 6.6). A live/dead fluorescent stain method was used to visualize probiotic
viability, where viable bacteria with intact cell membranes fluoresce green and dead
bacteria with damaged cell membranes fluoresce red. The confocal microscopy images
showed that all the free bacteria lost their viability after 2 h incubation in the gastric
fluids (Figure 6.5). Similarly, none of the cells inside the antacid-free alginate microgels
survived after exposure to the simulated stomach phase, indicating that hydrogen ions
(H+) from the gastric fluids rapidly diffused into the microgels and deactivated the
probiotic bacteria (Figure 6.5 and 6.6). Conversely, many of the cells remained viable in
the microgels containing Mg(OH)2 or CaCO3 after exposure to the stomach phase (Figure
6.5). After 2 h gastric digestion, there was a 1.5 log10 CFU reduction in the number of
viable bacteria in the microgels containing Mg(OH)2 and a 1.0 log10 CFU reduction for
the microgels containing CaCO3 (Figure 6.6). This result highlighted the ability of the
antacids to protect the probiotics against acidic gastric conditions. Our previous study
showed that the pH inside Mg(OH)2-loaded alginate microgels remained close to neutral
when they were incubated in acidic gastric fluids for 2 h [144]. This suggests that the
level of insoluble Mg(OH)2 inside the microgels was sufficient to neutralize the gastric
fluids throughout the entire incubation time. This phenomenon was probably because the
Mg(OH)2 particles only dissolved slowly in the gastric fluids [144]. The microgels
containing CaCO3 gave even better gastric protection than the ones containing Mg(OH)2
(Figure 6.6). After exposure to the intestinal phase, no viable cells were detected for the
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microgels containing Mg(OH)2, which corresponded to a greater than 5.43 log10 CFU loss
in cell viability. On the other hand, the microgels containing CaCO3, only suffered a 2.5
log10 CFU reduction. These results suggest that CaCO3 also had a better protective effect
on cell viability than Mg(OH)2 in the small intestinal phase.
The origin of the different protective effects of Mg(OH)2 and CaCO3 is still
unclear. There are several possible reasons that might attribute for this observation.
Firstly, the slowly released calcium ions might interact with bile salts or intestinal
enzymes and thereby reduce cell injury. The bile salts in the small intestine are known to
have a strong antimicrobial activity due to their ability to disrupt the structure of the cell
membrane and trigger DNA damage [260]. Secondly, the cryo-SEM images suggested
that CaCO3 crystals had a larger particle size than Mg(OH)2 crystals, which may have
reduced their dissolution rate or sterically hindered the ability of hydrogen ions to diffuse
through the hydrogels [261]. Third, the released calcium ions may have cross-linked the
alginate molecules in the hydrogel thereby reducing the pore size and inhibiting
diffusion. Fourth, the size of the microgels containing CaCO3 was larger than the ones
containing Mg(OH)2, which would have also slowed down diffusion processes [262].
Clearly, further work is required to work out the detailed physicochemical mechanisms
underlying the difference between the two types of antacids.
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Figure 6.5 Fluorescence confocal microscopy images of viable bacteria in different
systems after exposure to successive GIT stage (stained with LIVE/DEAD BacLight
Bacterial Viability Kit). Red indicates live cells, while green indicates cell with damaged
membrane.
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Figure 6.6 Survival number of cells encapsulated by alginate beads in the absence and
presence of antacid agent (Mg(OH)2 or CaCO3) after simulated gastrointestinal digestion.
6.4 Conclusion
In order to colonize the colon, probiotics must survive the harsh conditions they
experience during passage through the upper gastrointestinal tract. In particular, they
must resist deactivation by the deleterious actions of acids and bile salts within the gut. In
this study, we showed that antacid-loaded microgels could improve probiotic survival
under both stomach and small intestine conditions. It was postulated that the antacids
helped maintain neutral pH conditions within the interior of the microgels as they passed
through the highly acidic gastric fluids, thereby protecting the probiotics trapped inside
them. CaCO3 proved to be a more effective antacid than Mg(OH)2 at protecting the
probiotics for reasons that are currently unknown. Overall, the microgels developed in
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this work may be useful for encapsulating, protecting, and delivering sensitive probiotics
in functional foods, supplements, and pharmaceuticals. Future work will focused on
determining the mucoadhesion properties of the encapsulated probiotics within the
intestinal mucosa.
!
!
!
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CHAPTER 7
CONCLUDING REMARKS

Emerging evidence have support the opinion that gut microbiota dysbiosis is
associated with the onset and progress of several chronic disease, such as inflammatory
bowel disease, diabetes, and obesity. Intrinsic and environmental factors can influence
gut microbiota composition and diversity. Dietary intervention has been recognized as a
powerful method for microbiota modification, even more effective than gene. However,
the interaction between dietary component and gut microbiota is bidirectional, indicating
that gut microbiota can work on administrated xenobiotics. Gut microbiota metabolism
on xenobiotic will activate, deactivate or toxify the parent compound. There’re trillions of
bacteria co-evolved with human and residing in human body, while only some species or
strains has the metabolizing capacity. Most of the metabolizing capacity of bacteria
remains unknown. Besides, genus Bifidobacterium is regarded as probiotic, however,
research focuses on bacteria secretion bioactivities is kind of overlooked. To perform the
host health benefits, probiotic has to reach the site with sufficient amount. However, it’s
hard for bifidoabcteria to pass through the digestive system successfully. Because both
high acid condition in stomach and bile salts in small intestine are detrimental for cells.
Therefore, it’s necessary to develop an effective oral delivery system to help probiotic
reach colon with abundant cells.
In this dissertation, the impact of dietary citrus components was demonstrated in
unchallenged mice and colitic mice model. Our results demonstrated that oral intake of
limonin and nobiletin modified mice fecal microbiota. In colitic mice, gut microbiota
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dysbiosis was partially reversed by nobiletin intervention. Mice inflammation induced by
DSS was inhibited by nobiletin treatment, which was proved by reduced disease activity
index, lower histological score and inflammatory cytokines in colon mucosa. The strong
anti-inflammation of nobiletin was partially contributed by nobiletin metabolites, which
was produced by gut microbiota. Gut microbiota in colon deconjugated the nobiletin
metabolite conjugates. Therefore, we isolated and identified the bacteria (Isolate G7) with
deconjugation capacity, who belongs to species Bifidobacterium pseudocatenulatum.
Except the deconjugation potential of Isolate G7, its secretion has strong antiinflammation and anti-cancer capacity. Isolate G7 interrupted the NF-!B pathway in cell
RAW 264.7. Isolate G7 secretion performed its anti-cancer ability on human colon cancer
cell HCT116 by promoting cell apoptosis, arresting cell cycle and downregulating gene
expression of wnt signaling. Together, our results suggested that dietary components and
gut microbiota could interact with each other, and gut microbiota and dietary component
worked together to inhibited mice inflammation, providing a scientific basis for using
dietary nobiletin as a nutraceutical to promote gut health.
Accumulating studies have suggested that probiotic encapsulation can help to
increase cell viability after gastrointestinal digestion. To increase the efficiency of the
delivery system, antacid agents were used as gatroprotective agent. Our results indicated
that both cells and antacid agents can be encapsulated into alginate micorgels. The
micorgels keep intact during the gastrointestinal digestion. Most importantly, the system
could protect cells from acidic condition in simulated gastric juice and antacid agentCaCO3 could help to protect from bile salts in the simulated small intestine fluid also.
Overall, the microgels developed in this work may be useful for encapsulating,
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protecting, and delivering sensitive probiotics in functional foods, supplements, and
pharmaceuticals. The dissertation present here provides important knowledge concerning
the interaction between gut microbiota and dietary components and the beneficial effect
of probiotics and developed an effective delivery system for sensitive probiotic or
proteins.
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